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Although medical devices and biomaterial implants are used clinically in a variety 
of applications, the process of implanting them damages local tissue and initiates a 
localized non-specific inflammatory response that is detrimental to device performance.  
Extensive research efforts have focused on developing material surface treatments and 
systems to deliver anti-inflammatory agents to prevent biofouling and abrogate 
biomaterial-mediated inflammation.  Traditional surface modification strategies are 
capable of reducing protein adsorption and cell adhesion in vitro; however, their use as 
long-term implant coatings is limited due to reduced non-fouling behavior, continued 
inflammation and fibrous encapsulation.  This work aims to address these limitations by 
developing a novel and versatile implant coating with non-fouling properties using a 
system based on hydrogel microparticles (i.e. microgels), which offers many material 
advantages over current methods.  The overall objective of this project was to evaluate 
host responses to these microgel coatings.  Using the rationale that macrophages are the 
key mediators of inflammatory and regenerative responses our central hypothesis was 
that macrophage adhesion and subsequent activities can be modulated, and the intensity 
of the foreign body response to biomaterials can be reduced using these novel coatings.   
 As a first step toward testing this hypothesis, we characterized the surface 
properties of the microgel coatings using multiple techniques.  Microgel coatings were 
synthesized from poly(N-isopropyl acrylamide)-co-acrylic acid covalently crosslinked 
with poly(ethylene glycol)-diacrylate and deposited onto a clinically relevant substrate, 
poly(ethylene terephthalate).  We found that microgel coatings can be successfully 
 xxi
deposited using a simple spin coating technique, and the incorporation of a photoaffinity 
label enables covalent attachment to the substrate and enhances long-term stability.  We 
have confirmed the presence of nitrogen-rich pNIPAm microgel particles on the surface 
of PET and generated a homogeneous monolayer coating.  Microgel particles effectively 
covered material defects commonly present on the surface of the underlying PET 
substrate.  The ability to generate conformal and complete microgel coatings on 
heterogeneous/rough, biomedically relevant materials is a major advantage of this 
strategy over existing polymer chain grafting approaches.  Importantly, using 
radiolabeled protein assays, we determined that microgel-coated samples also adsorbed 
significantly lower levels of human fibrinogen compared to unmodified PET controls.  
  Further characterization of these materials involved the evaluation of cellular 
responses using an in vitro culture system to model acute leukocyte interactions with 
biomaterial surfaces.  Macrophages were cultured for 48 h on biomaterials, and adherent 
cells were imaged and scored for viability, adherent density, and spreading area.  We 
demonstrated that microgel coatings significantly reduced the adhesion and spreading of 
macrophages compared to PET controls using a murine macrophage cell line, as well as 
primary human blood-derived monocytes.  The low levels of in vitro cell adhesion and 
spreading combined with the protein adsorption-resistance characteristics on the 
microgels provide indirect evidence that these coatings impart non-fouling properties to 
biomaterial supports.   
 Implanted materials were then evaluated for early cellular responses in the 
intraperitoneal cavity of mice, a rigorous model of acute inflammation.  Analyses of 
explanted biomaterials using immunofluorescence staining techniques revealed that 
 xxii
microgel-coated samples significantly reduced the density of surface-adherent cells; 
additionally, fewer CD68+ macrophages were observed on these samples.  Moreover, 
adherent cells were harvested and immunostained intracellularly for a panel of 
inflammatory cytokines (TNF-α, MCP-1, IL-1β, and IL-10), and were then analyzed by 
flow cytometry to quantify relative cytokine levels.  We demonstrated that microgel-
coated samples exhibited significantly lower levels of pro-inflammatory cytokines in 
adherent leukocytes compared to unmodified PET, indicating that these coatings 
modulate cellular pro-inflammatory activities.  Microgel-coated samples did not elicit 
pro-inflammatory cytokine expression beyond levels associated with the surgical 
procedure (sham group); therefore, increased cytokine expression was associated with 
leukocyte adhesion to the implanted PET biomaterial.  These reductions of in vivo 
leukocyte adhesion and pro-inflammatory cytokine expression associated with the 
microgel coating contrasts with results of other non-fouling surface treatments.   
 Finally, we used an established model of chronic inflammation to evaluate these 
coatings for their efficacy at longer implantation time points.  Unmodified PET controls, 
microgel-coated samples, and EG3 SAMs were implanted subcutaneously for 4 wk.  
Explants were processed histologically and stained for various markers.  Collagen 
staining demonstrated that the microgel coatings significantly reduced fibrous capsule 
thickness, and those capsules appeared less compact and structurally ordered than PET 
controls.   Microgel-coated samples also contained significantly fewer total cells within 
the capsule.  Additional sections were stained for the macrophage marker CD68 using 
immunohistochemical methods to determine the inflammatory cellular profile at the cell-
material interface.  Unexpectedly, microgel-coated samples contained proportionately 
 xxiii
more CD68+ cells (relative to total cell numbers) than PET controls.  Sections were also 
scored for multinucleated FBGC, but no significant differences were found among 
treatment groups.   
In summary, this research has established a simple and reproducible method of 
surface functionalization to create effective coatings that resist protein adsorption and 
leukocyte adhesion.  Collectively, these results demonstrate that microgel particles can be 
applied as relatively stable implant coatings to modulate inflammation and achieve more 
desirable host responses in vivo with the potential to extend implant lifetime.  This work 
is innovative because it applies hydrogel particles to the development of a novel micro-
scale implant coating.  Our strategy offers unique control over synthesis parameters with 
the possibility of generating complex coatings onto a variety of biomedically-relevant 
materials.  Furthermore, this research provides the foundation for developing a hydrogel-
based coating system incorporating various bioactive signaling agents within a low-
fouling background.  Such a system will support controlled interactions with 








 Medical devices and biomaterial implants are used clinically in a variety of 
applications, and their performance is critical to a patient’s overall health and quality of 
life.  During implantation, surgical procedures injure microvasculature and surrounding 
tissues, initiating a localized inflammatory response.1  Although inflammation recruits 
native cells for remodeling and regenerating damaged tissue, persistent inflammatory 
stimuli significantly interfere with implant function and often result in device failure.  
Adverse host responses to implanted biomedical devices include thrombogenic responses 
on vascular grafts,2, 3 degradation and stress cracking of pacemaker leads,4, 5 tissue 
fibrosis surrounding mammary prostheses,6 osteolysis and loosening of orthopaedic joint 
prostheses,7, 8 reactive gliosis around neural probes,9 and degradation in biosensor 
function.10   
The host response to implanted biomaterials and tissue-engineered constructs is 
regulated largely by cell-material interactions.  Immediately following implantation, 
proteins and other biomolecules present in the blood plasma and biological fluids rapidly 
adsorb onto the surface of biomaterials.  This process occurs more rapidly than cell 
recruitment to the implantation site, and this complex protein milieu serves as an 
adhesive substrate supporting integrin receptor-mediated attachment of inflammatory 
leukocytes.11-13   
Persistent inflammatory stimuli lead to insufficient healing of local tissue at the 
device interface.  Macrophages fuse and form multinucleated FBGCs,14, 15 which have 
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been implicated in biodegradation of polymeric implants.16, 17  Additionally, fibroblasts 
recruited to the implant site generate a collagenous fibrous capsule around the implant.  
Long-term tissue fibrosis is particularly limiting for interactive implants such as 
biosensors, biomedical leads and electrodes, encapsulated cells, and drug delivery 
systems, because it impedes exchange of nutrients and cellular byproducts with the 
surrounding medium.10, 18-24 
Extensive research efforts have focused on modifying material properties via 
surface treatments to generate more biocompatible implants, with the goal of 
appropriately integrating the device without eliciting undesirable effects.25  Traditional 
strategies have aimed to develop non-fouling surface treatments to prevent protein 
adsorption and leukocyte adhesion (i.e. biofouling).  Several passivation strategies have 
been explored to achieve this goal, including preadsorption of material surfaces with less 
inflammatory proteins or cells.26-28  
Thin-layer polymeric coatings offer more substantial routes to reduce acute 
inflammatory responses, and these have been applied as molecularly thin SAMs, polymer 
brushes, and thin or bulk hydrogels.  While these systems have indeed reduced biofouling 
and inflammation, significant limitations persist.  SAMs are limited by lack of stability 
and mechanical properties, and their use is confined to a limited number of material 
substrates.29, 30  Polymer brushes also have limitations, including uncontrolled/insufficient 
grafting density or the requirement of an initiator on the material surface when using 
“grafting to” and “grafting from” methods, respectively.31, 32  Extensive research efforts 
have focused on hydrogel-based implant coatings, which offer many advantages over 
traditional surface modification strategies, including a viscoelastic network structure, 
 3
tunable material characteristics, incorporation of multiple chemical functionalities, nano-
scale dimensions with complex architectures, and the ability to deposit onto a variety of 
material substrates.33-37  Many of these techniques have effectively reduced protein 
adsorption and cell adhesion in vitro; however, they suffer from inadequate long-term 
stability and have only marginally reduced inflammation in vivo.  Despite considerable 
research efforts, surface coatings that eliminate biofouling and fibrous encapsulation over 
the lifetime of a device have not been attained.     
Microgels are colloidally stable hydrogel particles that retain many of the same 
material properties as their macrogel counterparts, including phase transition behavior 
and a viscoelastic network structure that enables mass transport.38  However, they offer 
many advantages over traditional hydrogel materials, such as colloidal stability, unique 
control over synthesis parameters, and the ability to incorporate co-monomers or 
biomolecules to achieve desirable properties.   
In this work, microgel coatings were synthesized from poly(N-isopropyl 
acrylamide)-co-acrylic acid covalently crosslinked with PEG-diacrylate and deposited 
onto a clinically relevant substrate, PET.  The overall objective of this project was to 
evaluate host responses to these microgel coatings.  Using the rationale that macrophages 
are the key mediators of inflammatory and regenerative responses our central hypothesis 
was that macrophage adhesion and subsequent activities can be modulated, and the 
intensity of the foreign body response to biomaterials can be reduced using these novel 
coatings.  The overall objective was accomplished by testing our central hypothesis 
according to the following specific aims: 
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Aim 1: Characterize the surface properties of microgel coatings and evaluate in vitro 
inflammatory cell responses to these materials. 
Our working hypothesis was that PEG-based microgel coatings will significantly reduce 
in vitro material biofouling.  PNIPAm-co-PEG microgel particles were synthesized via 
free radical precipitation polymerization, deposited onto PET disks using a spin coating 
process, and covalently cross-linked onto the substrate.  We characterized these coatings 
using the surface techniques XPS and AFM to identify chemical characteristics of the 
material and determine uniformity of the coating.  Using radiolabeled human fibrinogen, 
we determined the extent of protein adsorption to our model surfaces.  We also tested this 
hypothesis using in vitro culture systems, including an established murine macrophage 
cell line and isolated primary human monocytes, to determine the efficacy of microgel 
coatings in reducing cell adhesion.   
 
Aim 2: Evaluate in vivo acute and chronic host responses to microgel coatings. 
Our working hypothesis was that the addition of microgel-based coatings to the surface 
of PET would modulate in vivo host responses by reducing leukocyte adhesion and 
subsequent cellular activity and limiting long-term fibrosis.  We first tested this 
hypothesis by implanting samples in the intraperitoneal cavity of mice to mimic acute 
inflammation.  Explants were evaluated to determine the extent of leukocyte adhesion 
using immunofluorescence staining methods.  In addition, we investigated the 
inflammatory activity of these cells by staining them for a panel of pro- and anti-
inflammatory cytokines and then quantifying expression using flow cytometric analysis.  
An established model of chronic inflammation was used to evaluate long-term host 
 5
responses to microgel coatings implanted in subcutaneous pockets of rat dorsa.  Explants 
were processed histologically and stained to determine the extent of fibrous encapsulation 
and to quantify levels of capsule-associated macrophages and foreign body giant cells 
implicated in ongoing foreign body reactions and long-term material degradation. 
This work is innovative because it applies hydrogel particles to the development 
of a novel micro-scale implant coating.  Furthermore, this research provides the 
foundation for developing a hydrogel-based coating system incorporating various 
bioactive signaling agents within a low-fouling background.  Such a system will support 
controlled interactions with inflammatory cells, which will enable unprecedented 
regulation of host responses to implanted biomaterials.  Our microgel-based coating 
strategy offers significant advantages over traditional surface treatments including (i) 
precise control of synthesis parameters in terms of particle composition and structure, (ii) 
the ability to generate complex architectures and/or functionalities, including controlled 
drug release, (iii) the ability to generate complex mosaic-like coatings containing 
variations in particle composition and/or spatial arrangement, and (iv) deposition onto a 
variety of material substrates, including biomedically-relevant materials. 
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CHAPTER 2 





Host Foreign Body Response 
Biocompatibility is typically defined as the ability of a material or device to 
perform with an appropriate host response in a specific application;25 the biocompatibility 
of a material with tissue has generally been described in terms of acute and chronic phase 
inflammatory responses.39  Surgical procedures injure microvasculature and tissue 
surrounding the implanted device, initiating a localized non-specific inflammatory 
response (Figure 2.1).1  The severity and extent of the response to an implanted material 
directly affects the probability for its successful integration.   
 
 
Figure 2.1: Events of host foreign body response to implanted materials.  Neutrophils 
and monocytes recruited by stimulatory cues emigrate from the vasculature and adhere to 
the layer of adsorbed proteins on the implant surface (phases 1-3).  Differentiated 
macrophages become activated, secreting a variety of inflammatory mediators, and often 
fuse into multinucleated foreign body giant cells (phases 4-6).  Fibroblasts infiltrate the 
site and generate a collagenous fibrous capsule around the implant (phase 7).  BV: blood 
vessel, PMN: polymorphonuclear leukocyte, MC: immature monocyte, MΦ: 
differentiated macrophage, FBGC: multinucleated foreign body giant cell, FB: fibroblast. 
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Acute inflammation comprises the primary sequence of events following 
implantation, and it typically characterizes the first 24 to 48 hours of this reaction (phases 
1-5 in Figure 2.1).  Immediately following implantation, proteins and other biomolecules 
present in the blood plasma and biological fluids rapidly adsorb onto the surface of 
biomaterials.  This process occurs more rapidly than cell recruitment to the implantation 
site; therefore, the composition and configuration of this complex protein milieu dictates 
subsequent cellular responses.11-13  During this phase of the inflammatory response, 
stimulatory signals at the site of implantation initiate integrin receptor-mediated 
leukocyte recruitment, adhesion to the implant surface, and activation.40-42  Although 
injury initiates the inflammatory response, chemicals released from plasma, cells, and 
injured tissue continue to mediate the response proximal to the implant and determine the 
overall local tissue response.39, 43   
Short-lived polymorphonuclear leukocytes (e.g. neutrophils) initially release 
damaging lysosomal proteases and oxygen-derived free radicals locally1, 44 but are then 
replaced by inflammatory monocytes and macrophages.39  The layer of surface-adsorbed 
proteins modulates macrophage phenotype and subsequent functions, including 
phagocytosis, cytokine expression, and fusion into foreign body giant cells (FBGCs).12, 13  
Professional phagocytes macrophages are considered the key mediators of implant-
associated inflammation due to their distribution and motility, and their ability to 
generate a multitude of biologically active products.45-47  They play central roles in 
directing both inflammatory and regenerative responses associated with implanted 
biomaterials.48-50   
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Persistent inflammatory stimuli lead to insufficient healing of local tissue at the 
device interface.  The hallmark of a chronic response is fusion of monocyte-derived 
macrophages to form multinucleated FBGCs,1, 39 a complex process involving numerous 
molecules (phase 6 in Figure 2.1).14, 15  FBGCs have been implicated in biodegradation 
of polymeric implants through surface oxidation and enzymatic degradation.16, 17, 51  
Additionally, fibroblasts recruited to the implant site generate a thick fibrous capsule 
around the implant (phase 7 in Figure 2.1).  This process is differentiated from the 
normal healing response, in which fibroblasts and vascular endothelial cells at the 
implant site proliferate and deposit a bed of collagen to create soft, pink granular tissue.  
The latter wound healing response is dependent on the level of tissue damage from 
surgical incision and the ability of cells to regenerate the local area, but this usually 
results in fibrosis and scar tissue formation.  These cellular and tissue responses often 
impair in vivo device performance, and the extent of the host FBR to a biomaterial or 
implanted device depends largely on the form and topography of the material.1 
 
Chemical Mediators of Inflammation 
The inflammatory response comprises a highly complex cascade of events 
orchestrated by a variety of stimulatory and inhibitory molecules mediating leukocyte 
chemotaxis, adhesion, activation, and aggregation, as well as phagocytosis.  In response 
to vascular injury near the site of implantation, leukocytes emigrate through vessel walls 
into the biomaterial exudate.  Increased leukocytic adhesion involves specific interactions 
between complementary adhesion molecules present on the leukocyte and endothelial 
surfaces.1  Inflammatory agents, namely cytokines IL-1 and TNF-α, stimulate increased 
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surface expression of these adhesion molecules.  This enables leukocytes to adhere to the 
endothelium of blood vessels and transmigrate through the wall into the tissue exudates.  
Their chemotaxis is mediated by stimuli including complement protein fragments, 
mediators of the kinin, clotting and fibrinolytic systems, and products created by 
leukocytes themselves.39  In addition, soluble lymphokines released from activated T 
lymphocytes, such as monocyte chemotactic factor (MCF), attract macrophages while 
migration inhibition factor (MIF) immobilizes them at the site of injury.  Other factors 
such as macrophage activating factor, macrophage fusion factor, and specific macrophage 
arming factors then activate the immobilized cells and promote their interaction with the 
implant.  Leukotriene B4, an intermediate of arachidonic acid metabolism, also provokes 
inflammation by affecting leukocyte chemotaxis and lysosomal enzyme release.39  In 
addition, protein degradation products such as fibrinopeptide B (from fibrin) and 
kallikrein (a clotting cascade enzyme) have chemotactic activity. 
Soluble hormone-like factors called cytokines are produced by a wide variety of 
cell types including lymphocytes, monocytes, platelets, fibroblasts, and keratinocytes.  
These secreted proteins exert diverse biological effects on various target cells and 
regulate both immunological and inflammatory host responses by serving as intracellular 
messengers.39  Specifically, TNF and IL-1 stimulate the production of a wide variety of 
cells and also initiate cell migration, differentiation, and tissue remodeling.1 
The principle soluble mediator of macrophage activation is macrophage activating 
factor (MAF), also known as interleukin-2 (IL-2), another T cell-derived lymphokine.  
Once recruited and activated macrophages can, themselves, release a variety of chemicals 
to drive inflammation-associated activities.  These include certain cytokines, interferons 
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(IFN), prostaglandins, lysosomal enzymes, leukocytic pyrogen, and other cytotoxic 
agents.39  Macrophage-secreted interleukin-1 (IL-1) activates T cells to produce more IL-
2 (activating more macrophages), stimulates fibroblast activity, and induces collagen and 
collagenase synthesis.39  Colony stimulating factor (CSF), another cytokine produced by 
a variety of activated inflammatory cells, can also stimulate the production of phagocyte 
precursors or activate additional macrophages.  Interferon Type 1 is synthesized by 
activated macrophages under the control of prostaglandins and CSF; prostaglandin E 
inhibits the synthesis of interferon, while CSF stimulates it.  Interferon Type 1 can then 
feed back and further activate macrophages by enhancing their phagocytic capability. 
In addition to downregulating IFN activity, prostaglandins play other important 
positive and negative regulatory roles.  They have been shown to increase the numbers of 
both immunoglobulin Fc receptors and the lectin concanavalin A receptors on 
macrophage membranes.  Macrophage-produced prostaglandin E2 (PGE-2) inhibits 
proliferation of granulocyte-macrophage stem cells and will also inhibit macrophage 
spreading, adherence, and migration.  Glucocorticoids, powerful anti-inflammatory and 
immunosuppressive drugs, also inhibit macrophage function by interacting with 
corresponding surface receptors to inhibit synthesis and secretion of neutral proteases 
(especially plasminogen activator) and IL-1.39  
Macrophages also synthesize numerous complement components, including C3 
and Factor B.  C3b, a cleaved product of C3, further activates macrophages and also acts 
as an opsonin to enhance phagocytosis.  In addition, macrophages also release 
plasminogen activator, which cleaves plasminogen to plasmin.  Plasmin has multiple 
regulatory roles, including degrading fibrin into soluble products and cleaving C3 to the 
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active form C3b.  Certain lymphokines have been described to enhance phagocytosis 
mediated by ligand binding to both C3b and Fc receptors.  Leukocyte aggregation is 
another well characterized response to chemotactic factors, especially C5a and 
macrophage aggregating factor.39   
 
Protein Adsorption and Cell Adhesion 
Implanted biomaterials trigger a wide variety of unwanted responses, including 
inflammation, thrombosis, infection, and fibrosis.  In many cases, these adverse responses 
are associated with the rapid accumulation of large numbers of phagocytic cells, which is 
an important feature of the inflammatory reaction.52  Overall, cell adhesion to a material 
is dependent on protein adsorption profiles, surface chemistry, and material 
morphology.12, 53, 54  Chemical modifications to a surface induce changes in material 
compatibility that affect the overall biological response.13, 55-57   
Adsorption of biomolecules from multi-component solutions, such as plasma and 
biological fluids, is a dynamic process involving competition, rearrangements, and 
displacement of adsorbed species (the Vroman effect).58, 59  Material surface chemistry 
often drives hydrated biomolecules to partially release bound water molecules, leading to 
structural changes and reversible as well as irreversible physisorpton of biomolecules 
onto the surface.60  The composition and configuration of the adsorbed protein layer 
dictates which adhesive ligands will be exposed on these proteins, thus determining the 
adhesive nature of the surface.61  In particular, macrophage phagocytic activity, 
migration, and fusion to form FBGCs are influenced by adhesion to different proteins; 
therefore, the adhesive substrate affects cellular phenotype and function.13, 62, 63   
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Albumin, fibrinogen, and immunoglobulin (IgG) are the most abundant proteins 
in plasma; they are involved in competitive binding events at the surface of biomaterials 
and subsequently mediate adherence of PMNs.64  IgG and complement fragment C3b are 
natural opsonins and adsorb to biomaterials within seconds of implantation.46, 64  There 
are conflicting arguments about the necessity for complement C3 and IgG binding 
leukocytes to initiate acute inflammation.  McNally and Anderson63 determined that 
interactions between the leukocyte Mac-1 integrin and adsorbed C3b are an important 
adhesion mechanism on all serum-adsorbed surfaces.  A significant role for IgG has also 
been revealed; IgG depletion caused a significant decrease in initial adherent cell 
density,12 and adsorbed IgG also effectively activates monocytes, causes cell spreading, 
and FBGC formation.13  However, biomaterials implanted in mice with severe combined 
immunodeficiency or complement deficiency exhibit normal recruitment of phagocytic 
cells; therefore, neither surface-bound IgG nor complement activation are necessary in 
triggering acute inflammatory responses in vivo.64  Opsonization of particles likely 
involves multiple protein species.53  It is likely that combined adsorption of complement, 
IgG, and fibrinogen promotes strong interactions between leukocytes and biomaterial 
surfaces.52, 56, 63-66   
 
Integrins in Inflammation 
The generally accepted model for inflammatory cell-biomaterial interactions is 
that leukocytes interact with the layer of spontaneously adsorbed proteins rather than with 
the material itself.52  Moreover, when proteins bind hydrophobic surfaces they undergo 
conformational changes, causing them to unfold and develop strong bonds with the 
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surface.60, 65, 67  In particular, material-induced conformational changes of adsorbed 
fibrinogen are critical in the early phases of the foreign body reaction to biomaterials.65  
Fibrinogen adsorption probably induces changes in its tertiary structure leading to the 
exposure of previously hidden epitopes that help initiate adverse reactions.52  In addition, 
fibrinogen mediates platelet adhesion to surfaces and affects material blood 
compatibility.66   
Integrins are heterodimeric transmembrane receptors composed of α and β 
subunits.  β1 integrins are expressed ubiquitously on many cell types and are used in 
binding to extracellular matrix ligands and biomaterial surfaces.68  The β2 integrin (CD18) 
is expressed specifically on leukocytes.69  β2 subunits can associate with three unique α 
subunits (CD11a, b, or c) to form heterodimers, one of which is the Mac-1 integrin 
(CD11b/CD18, αMβ2).  These integrins are usually in resting state, but they can become 
rapidly activated by cytokines causing them to be adhesive to their counter-receptors on 
other cells, bacterial polysaccharides, or viral coat proteins.  These adhesive interactions 
enhance leukocyte attachment to the endothelium and subsequent extravasation to areas 
of inflammation, and they also assist in phagocytosis.40  Mutations in the β2 subunit can 
lead to life-threatening disorders such as leukocyte adhesion deficiency type 1 (LAD-1), 
which results in impaired endothelial cell adhesion and reduced extravasation.70  In 
addition, research supports a requirement for monocyte β2 subunits during initial 
adhesion to a surface, and both β1 and β2 subunits are utilized during the process of 
macrophage fusion into multinucleated foreign body giant cells.41  Leukocyte adhesion to 
a biomaterial surface stimulates transcription of genes for inflammatory mediators, such 
as cytokines, reactive oxygen intermediates, and tissue factor.63   
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On stimulated leukocytes, Mac-1 functions as a high affinity receptor for 
fibrinogen71, 72 and promotes phagocyte accumulation on biomaterial surfaces.73  In 
particular, a short sequence in the fibrinogen D domain was determined to be the minimal 
recognition sequence for this integrin.71, 74  This domain, γ190-202, is commonly known 
as P1 and represents less than one percent of the total fibrinogen molecule.73  The P1 
epitope is hidden in soluble fibrinogen, but adsorption onto the implant surface causes 
conformational changes, protein denaturation, and tight adherence of fibrinogen revealing 
its pro-inflammatory form.52, 72  A second eptiope (γ377-395) in the D domain known as 
P2 interacts with Mac-1 only when adsorbed to a surface, as well.72, 74   
Moreover, thrombin-mediated conversion of fibrinogen to fibrin also exposes 
both P1 and P2 epitopes.  Phagocytes may recognize fibrinogen adherent to biomaterials 
or medical implants as fibrin and respond by initiating a series of inflammatory and 
wound-healing responses meant to ward off infection and initiate wound healing at sites 
of vascular injury.52  As an important component of the provisional matrix formed during 
wound healing,75 fibrin may be a universal cue triggering leukocytes and locally 
regulating their function.72  The extent of biomaterial-mediated P1 and P2 exposure 
appears directly related to the severity of inflammatory responses to a test panel of 
biomaterials, given their ability to mediate phagocyte adhesion and activation.52, 73  
Although it is evident that macrophages utilize the αMβ2 integrin to bind these motifs, it is 





Macrophage as a Central Regulator of Inflammation 
Different populations of macrophage exist including inflammatory, microbicidal, 
reparative, pro-angiogenic, pro-thrombotic, antigen presenting and immunosuppressive 
cells, resulting in diverse leukocyte functions.48  Research has shown that macrophages 
become unresponsive to subsequent signals after being initially stimulated by a particular 
cytokine.76  However, other results suggest that macrophage functions can adapt to 
changes in the environment and shift their phenotype rather than developing into discrete 
subsets.77, 78  “Classically activated” macrophages are stimulated by microbes, opsonized 
particles, and interferon-γ (IFN-γ).  These macrophages have a destructive phenotype, 
inducing cellular apoptosis and degrading tissue via matrix metalloproteinases; they also 
phagocytose opsonized particles and immune complexes, degrade matrix, and generate 
pro-inflammatory cytokines and chemokines.79, 80  By contrast IL-4, IL-10, IL-13, and 
TGF-β1 stimulate “alternatively activated” macrophages with an anti-inflammatory 
phenotype but an enhanced ability to present antigens and phagocytose particles or 
debris.48, 50, 81  Instead of causing tissue destruction, alternatively activated macrophages 
are involved in healing processes such as matrix synthesis and stabilization, and 
induction of cell survival, proliferation, and angiogenesis.79, 82  The balance of these 
macrophage phenotypes is necessary for proper healing and restitution of normal tissue. 
Due to their abundance, distribution, motility, responsivity, and versatility, 
macrophages are considered key mediators of implant-associated inflammation and the 
foreign body response, and they generate myriad biologically active products.46, 47, 83  
More than 100 substances are secreted by macrophages including hormones, neutral 
proteases, lysosomal hydrolases, chemotactic factors, arachidonic acid metabolites, 
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reactive oxygen intermediates, complement components, coagulation factors, growth-
promoting factors, and cytokines.  Lysosomal hydrolases and neutral proteases, active at 
low and neutral pH respectively, degrade carbohydrates and connective tissue 
components and generate inflammatory mediators such as C3b and kinins.39, 47   
Macrophages also have receptors on their surface for opsonins, namely the 
complement cleavage fragment C3b and the Fc portion of the immunoglobulin molecule.  
Membrane perturbation, through receptor-ligand binding and aggregation or 
internalization of receptor-ligand complexes, is believed to activate these cells. 39  These 
activated macrophages then exhibit increased phagocytic activity and upon attachment to 
a surface, spread more rapidly and extensively than do normal resting macrophages.1  
Upon contact of the cell plasma membrane with various surface-reactive materials or 
soluble substances that induce phagocytosis, macrophages undergo an associated 
“respiratory burst” and generate highly reactive oxygen metabolites (superoxide anions 
and hydroxyl radicals).83 39  These cellular byproducts can have disastrous effects on 
implanted materials, degrading their surface and leading to device failure.46     
Due to the large size disparity between cells and implanted materials, it is 
hypothesized that monocytes and macrophages fuse to form large multinucleated foreign 
body giant cells (FBGCs).1, 83  In addition to the αMβ2 integrin, the macrophage mannose 
receptor (MMR) has been identified as critical to FBGC formation, which may itself 
occur by a phagocytic mechanism.84  Macrophage fusion is accompanied by considerable 
cytoplasmic expansion, resulting in FBGCs exhibiting as many as 100 nuclei.85  
Multinucleated giant cells have been observed in chronically inflamed tissues, yet the 
physiological significance and precise role of FBGCs at the tissue-material interface is 
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poorly defined.  Emerging research suggests two distinct possibilities: (i) macrophage 
fusion into FBGCs could be a mechanism for promoting inflammatory cell survival by 
escaping apoptosis,86 or (ii) FBGCs could serve a more wound healing function by 
sequestering phagocytic cell activities at the cell-substrate interface to maintain the 
response at a local, less activated level.41  Other cell populations, such as T lymphocytes, 
also play important roles in the attraction of macrophages, their formation into FBGCs, 
antigen presentation, and phagocytic abilities.87  Therefore, it is likely that the FBR 
phenotype (inflammatory vs. reparative) and intensity depends on a composite response 
of macrophages and lymphocytes acting in concert.50, 88 
 
Hydrogel materials for biomedical and biotechnological applications 
Extensive research efforts have focused on hydrogel-based implant coatings, 
which offer many advantages over traditional surface modification strategies including 
self-assembled monolayers and polymer brushes.29, 31, 32  They are particularly useful in 
biomedical and biotechnological applications due to their high water content and soft 
consistency.89  Structurally unique three-dimensional architectures can be formed by 
cross-linking hydrogel building blocks in the form of nanoparticles, microspheres, or 
dendrimers.90  Responsive polymers lend themselves to a variety of applications.  A 
number of polymeric systems, including chitosan, PEO-PPO-PEO triblock copolymers, 
and pAAc copolymers, possess thermoresponsive gelation properties.91  
Thermoresponsive pNIPAm is a generally biocompatible hydrogel92 and has been studied 
extensively.  At a lower critical solution temperature (LCST) pNIPAm undergoes a 
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reversible volume phase transition and hydrophobically collapses upon itself, expelling 
water in an entropically favored event.89   
By controlling the gelation properties, bulk hydrogels (i.e. macrogels) can be 
formed in situ in the presence of cells or used to address in vivo tissue defects.93, 94  These 
responsive hydrogels are also utilized as delivery vehicles for bioactive materials, 
offering controlled release of drugs or proteins.90, 91, 95-97  Recently, these systems have 
been utilized in the development of vaccines, as well; examples include delivery of 
combination drugs, such as chemo- and immunotherapeutic drugs was used to treat 
cancer,98 and delivery of improved non-viral vaccines to facilitate priming of the immune 
system.99, 100  The release kinetics of macromolecular delivery systems are critical, and 
thermoresponsive polymers have been used to obtain on-off release profiles in response 
to stepwise temperature changes.92, 101  Hydrogel synthesis parameters can be well 
controlled, enabling incorporation of biological features such as pendant peptides to 
create bioactive scaffolds.  Spatial patterns and molecular gradients of biomolecules, such 
as adhesion motifs, can be used to investigate and direct cell-surface interactions.93, 102, 103  
Bioactive hydrogel networks with incorporated protease degradation sites encourage 
more advanced responses, as in the case of wound healing applications involving 
enzymes associated with cell migration.104  Hydrogel polymers also continue to gain 
attention in the creation of more biocompatible materials.  The development of such 
novel implantable materials offering efficacy in vivo, as well as long-term stability, is 
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INFLAMMATION AND DEVICE PERFORMANCE 
Medical devices and biomaterial implants are used clinically in a variety of 
applications, and their performance is critical to a patient’s overall health and quality of 
life.  Surgical procedures injure microvasculature and tissue surrounding the implanted 
device, initiating a localized non-specific inflammatory response.1  Although 
inflammation recruits native cells for remodeling and regenerating the damaged tissue, 
persistent and inflammatory stimuli significantly interfere with implant function and 
often result in device failure.  Adverse host responses to implanted biomedical devices 
include thrombogenic responses on vascular grafts,2, 3 degradation and stress cracking of 
pacemaker leads,4, 5 tissue fibrosis surrounding mammary prostheses,6 osteolysis and 
loosening of orthopaedic joint prostheses,7, 8 reactive gliosis around neural probes,9 and 
degradation in biosensor function.10   
In the case of indwelling biosensors, including continuous glucose sensors, cell-
mediated inflammatory responses and fibrous scarring adversely impact sensor 
performance, including fluctuations in biosensor sensitivity, decreased response time, and 
material degradation.105-107  Accurate performance of glucose biosensors is critical to 
monitoring patient health, because diabetes is among the leading causes of death in the 
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United States.108  Currently, many glucose sensors only function reliably for a few days 
in vivo before failing.18  It has been suggested that these implants may require a 
stabilization period during fibrous capsule development, resulting in erroneous analyte 
measurements for weeks after implantation.109, 110  Novel, probably multi-pronged, 
approaches are needed to abrogate long-term inflammatory responses and extend the in 
vivo lifetime of medical implants in order to avoid the need for multiple surgical 
procedures. 
 
ANTI-INFLAMMATORY COATING STRATEGIES 
The severity and extent of the biological response to an implanted biomaterial or 
device influences the probability for its successful integration with surrounding tissue, as 
well as overall device performance.  Initial stages of the FBR are dictated largely by the 
extent of injury and surgical technique, implantation site, implant shape and size, material 
chemical and physical properties, and local and systemic health of the recipient.1, 111-113 
Significant research efforts have focused on modifying material properties using various 
anti-inflammatory surface coatings to generate more biocompatible implants. 
 
I. Passive Strategies: Non-fouling Surface Treatments 
The initial stages of the FBR involve non-specific protein and biomolecule 
adsorption and subsequent leukocyte adhesion onto the biomaterial surface, events 
termed “biofouling.”  It is generally believed that reducing biofouling can ameliorate 
subsequent adverse inflammatory responses such as leukocyte activation and tissue 
fibrosis.  Several passive strategies have been explored to achieve this goal, including 
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preadsorption of material surfaces with less inflammatory proteins or cells.  Such 
passivation strategies are attractive, because they are relatively straightforward and 
simple.26, 27  However, these coatings suffer from a lack of stability as other proteins, 
such as fibrinogen, can passively displace preadsorbed proteins, such as albumin.  Even 
covalently-tethered non-adhesive proteins can be degraded by leukocytes, resulting in 
deposition of pro-inflammatory, adhesive components.  Approaches involving cell 
deposition onto surfaces prior to implantation offer a possible strategy to promote wound 
healing by encouraging mass transport and reducing fibrotic responses at the tissue-
implant interface.28  However, issues related to cell sourcing, host responses to the donor 
cells, and long-term stability limit these strategies. 
Non-fouling (protein adsorption-resistant) thin-layer polymeric coatings offer 
more substantial routes to reduce acute inflammatory responses.  The design 
requirements for implanted materials and devices vary considerably depending on the in 
vivo application and site of implantation.  In particular, non-fouling polymeric surface 
coatings for implantable biosensors must ideally conform to the following considerations: 
• Use of non-toxic materials 
• Effectively prevent in vivo biofouling  
• Appropriate thickness and permeability to allow analyte detection  
• Techniques to deposit coating onto a variety of materials and architectures 
• Mechanical, chemical, and electrical stability to withstand surface deposition, 
sterilization methods, implantation procedures, and in vivo environment. 
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Despite considerable research efforts, surface coatings that completely eliminate 
protein adsorption over the lifetime of a device have not been attained.  Nevertheless, 
significant progress has been made in understanding the mechanisms driving protein 
adsorption, and several chemical groups that resist protein adsorption have been 
identified.  Polyethylene glycol (PEG, -[CH2CH2O]n) has proven to be the most protein-
resistant functionality and remains the standard for comparison (Figure 3.1).114  PEG 
chain density, length, and conformation strongly influence resistance to protein 
adsorption.115, 116, 117  The mechanism of resistance to protein adsorption by PEG surfaces 
probably involves a combination of the ability of the polymer chain to retain interfacial 
water and the resistance of the polymer chain to compression, due to its tendency to 
remain an extended coil conformation.118-120  Other hydrophilic polymers, such as poly(2-
hydroxyethyl methacrylate),121 poly(N-isopropyl acrylamide),89, 122 poly(acrylamide), and 
phosphoryl choline-based polymers,123-126 also resist protein adsorption.  In addition, 
mannitol, oligomaltose, and taurine groups have emerged as promising moieties to 




Figure 3.1: Passive anti-inflammatory surface coating for 
biomaterials.  Hydrophilic polymeric coatings, such as PEG-based 
hydrogels, retain interfacial water molecules rendering them highly 
resistant to protein adsorption.   
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These coatings have been applied as molecularly thin self-assembled monolayers 
(SAMs), polymer brushes, and thin or bulk hydrogels (Table 3.1) capable of reducing 
protein adsorption and leukocyte adhesion.  SAMs are confined to inorganic, planar 
surfaces and are only stable short-term in aqueous environments, limiting their use as 
coatings for in vivo biosensors.30  Polymer brushes are more mechanically robust than 
SAMs and can be generated on non-planar surfaces, including colloidal suspensions and 
polymeric substrates.  Moreover, surface-initiated polymerizations allow control over 
functionality, grafting density, and thickness of the brushes.31, 32  Extensive research 
efforts have focused on hydrogel-based implant coatings, which are particularly useful in 
biomedical and biotechnological applications due to their high water content and soft 
consistency.89  Hydrogels offer many advantages over traditional surface modification 
strategies, including a viscoelastic network structure, tunable material characteristics, 
incorporation of multiple chemical functionalities, nano-scale dimensions with complex 
architectures, and the ability to deposit onto a variety of material substrates.33-37, 92, 93 
 
II. Microgel-Based Implant Coatings 
While bulk hydrogels have already realized potential in many biotechnological 
applications, micro- and nano-scale hydrogels have recently emerged to create the next 
generation of “smart” biomaterials.  Microgels are colloidally stable hydrogel particles 
that retain many of the same material properties as their macrogel counterparts, including 
phase transition behavior and a viscoelastic network structure that enables mass 
transport.38  However, they offer many advantages over traditional hydrogel materials, 
such as colloidal stability, unique control over synthesis parameters, and the ability to 
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incorporate co-monomers with desirable properties.  Microgels are commonly prepared 
via precipitation polymerization reactions, which can generate particles of desired size by 
optimizing synthesis parameters.130   
Thermoresponsive pNIPAm is commonly used in the development of microgels 
due to its predictable phase transition behavior.  By incorporating various co-monomers 
during synthesis, these so-called “smart” pNIPAm-based materials can respond to 
temperature, pH, light, and ionic strength.37  The introduction of functional groups, such 
as acrylic acid co-monomers, yields microgel particles with pendant acid groups serving 
as reactive sites for conjugation of biomolecules and expands the utility of these 
pNIPAm-based materials.131  Additionally, more structurally complex microgel-based 
systems have been developed with an inner core and outer shell.37  Such strategies lend 
themselves to the development of hydrogel-based materials for controlled drug delivery 
or applications targeting specific cells.131  Microgel systems also have great potential in 
the development of novel surface treatments for a variety of applications, including non-










Table 3.1: Examples of non-fouling ethylene glycol-based surface treatments.  
A • denotes materials that were only tested in vitro. 
Coating Structure Selected References 
Self-assembled monolayer 
Prime & Whitesides (1993) 30 • 
Chapman et al. (2001) 132 • 
Zhang et al. (2001) 133 • 
Polymer brush or surface graft 
Espadas-Torre & Meyerhoff (1995) 134 • 
Lee et al. (1997) 135 • 
Du et al. (1997) 136 • 
Zhang et al. (1998) 137 • 
Jenney & Anderson (1999) 138 • 
Shen et al. (2001) 139 • 
Otsuka et al. (2001) 140 • 
Boulmedais et al. (2004) 141 • 
Ma et al. (2004) 142 • 
Ma et al. (2006) 143 • 
Zhou et al. (2007) 144 • 
Waku et al. (2007) 145 • 
Cao et al. (2007) 146 • 
Hydrogel 
West & Hubbell (1995) 94 
Quinn et al. (1995) 147 
Quinn et al. (1997) 148 
Collier et al. (2004) 149 • 
Nolan et al. (2005) 89 • 
Singh et al. (2007) 122 • 
Yu et al. (2008) 150 
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III. Active Strategies: Delivery of Anti-inflammatory Agents 
In contrast to passive non-fouling surface treatments, coatings presenting anti-
inflammatory agents offer a more interactive and directed approach to modulate cell 
behavior.  Broad-spectrum drugs have typically been used to control chronic tissue 
inflammation.  However, orally administered drugs may not achieve adequate local 
concentrations, and their long-term systemic use can cause major side effects.  Therefore, 
it is desirable to deliver therapeutics locally in a controlled, site-specific manner to 
improve the tissue-material response.   
Various immunomodulatory agents can be immobilized onto non-fouling 
polymeric coatings or delivered in soluble form from the coating (Figure 3.2).  Possible 
strategies for controlled release of agents include passive diffusion from coatings or 
polyelectrolyte layers,151, 152 bioerodible/degradable coatings to release drugs by passive 
dissolution,153 swelling coatings that release drug by passive mechanisms, and 
hydrolysable or enzyme-degradable linkages to release the agent.154-157  These “smart” 
delivery systems offer several advantages over passive methods, including highly 
controlled presentation of immunomodulatory agents, control over reaction kinetics, and 
versatility through hybrid designs.  In addition to the basic requirements for passive 
coatings, designs for these bioactive coatings must consider the following properties: 
• Retain bioactivity of anti-inflammatory molecules for the intended lifetime 
• Optimal tethering distance for recognition of immobilized agents 
• Appropriate release profiles in terms of amounts, rates, total dosage, and release 
time (acute vs. chronic release) 
• Drug character (e.g. hydrophobicity), residence times, and stability 
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• Safety issues related to drug release (designed or accidental) 
• Agent-matrix (coating) interactions 
• Effects of material sterilization.   




Figure 3.2: Bioactive implant coatings to deliver anti-inflammatory 
molecules.  Representative schemes depict mechanisms for active 
delivery of various immunomodulatory agents to reduce leukocyte 




Examples of anti-inflammatory factors delivered from surface coatings are 
summarized in Table 3.2.  Dexamethasone (DEX) is a synthetic glucocorticoid hormone 
with many applications in biomedical research, including treatment of inflammatory 
responses.158  DEX modulates macrophage behavior and reduces the levels of numerous 
pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ.159, 160  DEX-
releasing coatings have reduced tissue inflammation and cell activation surrounding 
implanted glucose biosensors and neural implants.161-164  In addition, polypyrrole-based 
electrode coatings designed to electrically control delivery of DEX lowered the amount 




Table 3.2: Active surface treatments for biomaterial coatings. A • denotes 
materials that were only tested in vitro. 







Wadhwa et al. (2006) 165 • 
Kim & Martin (2006) 163 
Norton et al. (2007) 161 
Zhong & Bellamkonda (2007) 162 






Benkirane-Jessel et al. (2004) 151 • 
Schultz et al. (2005) 152 
Zhong & Bellamkonda (2005) 166 • 










Gerritsen et al. (2000) 168 
Wang et al. (2003) 169 • 
van Bilsen et al. (2004) 170 
Sung et al. (2004) 171 • 
Fu et al. (2005) 172 • 
Rele et al. (2005) 173 
Tseng et al. (2006) 174 • 
Du et al. (2007) 175 • 
IL-1Ra immobilized or soluble Kim et al. (2007) 176 • 





Nguyen et al. (2004) 178 • 
Su et al. (2005) 179 • 
Pan et al. (2006) 180 • 
Vitamin E passive release Hahn et al. (2004) 181 • 
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Heparin is a highly sulfated glycosaminoglycan with strong anti-coagulant 
activity, and it also exhibits anti-inflammatory properties.  It is synthesized and secreted 
by mast cells at sites of infection and inhibits endotoxin-induced monocyte activation.182  
Heparin pretreatment significantly attenuates leukocyte transmigration through its actions 
on P- and L-selectin42, 183 and the leukocyte-specific αMβ2 integrin, and it also binds 
cytokines and suppresses superoxide generation by neutrophils.182, 184  Heparin-based 
coatings have reduced protein adsorption, leukocyte extravasation from the vasculature, 
and recruitment to implant surfaces.170, 173-175   
Alpha melanocyte-stimulating hormone (α-MSH) is an endogenous linear peptide 
with potent anti-inflammatory properties.  In vitro, α-MSH reduced levels of pro-
inflammatory TNF-α while increasing levels of anti-inflammatory IL-10 in stimulated 
human monocytes.151  It stimulated production of the anti-inflammatory cytokine IL-10 
and revealed a less obstructive cell layer on coatings for tracheal prostheses.152  In 
addition, α-MSH inhibited nitric oxide production by stimulated microglia, and reduced 
the magnitude of electrical impedance of implanted neural implants.166 
Receptor antagonists, antibodies, and soluble receptors are endogenous molecules 
that competitively inhibit binding to the corresponding agonist, effectively acting as a 
molecular trap.   Decoy antagonists have been developed against pro-inflammatory 
cytokines, such as IL-1, as a strategy to regulate inflammation.185, 186  In one interesting 
study, a fusion protein of recombinant human IL-1 receptor antagonist and elastin-like 
polypeptide (IL-1ra-ELP) was formed and covalently immobilized onto SAMs.176  This 
fusion protein was able to prevent endotoxin-stimulated human monocytes from 
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differentiating, and reduced expression of pro-inflammatory cytokines while increasing 
the production of anti-inflammatory and pro-wound healing cytokines.  
Superoxide anions are potent cytotoxic oxidants secreted during macrophage 
phagocytosis.  Superoxide dismutase is an endogenous scavenger enzyme that catalyzes 
its breakdown into less reactive hydrogen peroxide and oxygen.  Superoxide dismutase 
mimetics (SODm) were developed as an anti-inflammatory mechanism.  When 
covalently attached to ultra high molecular weight polyethylene, neutrophil recruitment 
was significantly reduced.177 
 
EXISTING CONSIDERATIONS AND FUTURE PROSPECTS 
Biomaterial-mediated inflammation poses a complex problem, limiting the 
function of implanted devices and overall patient health.  Significant efforts have focused 
on developing passive non-fouling surface treatments to prevent protein adsorption and 
leukocyte adhesion, as well as active mechanistic approaches for the delivery of anti-
inflammatory agents.  While these coating technologies have reduced protein adsorption 
and cell adhesion in vitro, considerable fibrous encapsulation and adverse inflammatory 
responses are still evident following implantation.161, 170, 187  These marginal reductions in 
adverse inflammation can be attributed to persistent leukocyte adhesion and activation in 
vivo and sub-optimal pharmacodelivery.161, 188   
Although current polymeric coatings successfully modulate acute inflammatory 
events, new strategies will be critical to extend the in vivo lifetime and performance of 
implanted devices.   Coating designs will probably need to be material and application-
specific in order to achieve the desired in vivo response.  Biologically interactive implants 
are gaining considerable interest.  Tunable, stimuli-responsive materials and biomimetic 
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molecules may be able to actively direct cell behavior and activity surrounding the 
implant, encouraging more desirable interactions.33, 34  In addition, these “smart” 
materials will lend a higher degree of sensitivity and specificity to polymeric coatings, 
enabling tighter control over pharmacokinetics and complex dosing schemes using 
multiple biomolecules or drugs.  For instance, delivery of oligonucleotides have proved 
to be an effective strategy to down-regulate specific endogenous inflammatory factors.189  
These approaches may create less inflammatory macrophages and attract wound healing 
cells.  It will also be important to focus on successful integration of the device with 
surrounding tissue and regenerating damaged microvasculature.  Tissue integration is 
particularly important in neural and orthopedic applications.9, 11  In addition, the delivery 
of angiogenic factors may help facilitate in vivo performance of implanted biosensors by 
offsetting tissue fibrosis.161, 164, 190  Clearly, progress in the development of effective and 
long-term in vivo sensors will require the integration of multiple strategies and 
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Host responses to biomaterials control the biological performance of implanted 
medical devices, tissue-engineered constructs, and delivery vehicles for therapeutics.1, 191  
Upon implantation, synthetic materials dynamically adsorb proteins and other 
biomolecules which trigger an inflammatory cascade comprising blood coagulation, 
leukocyte recruitment and adhesion, foreign body reaction, and fibrous encapsulation.1, 
191  The foreign body reaction and ensuing fibrous encapsulation result in a 
physicochemical barrier that severely limits device integration and the in vivo 
performance of numerous devices, including chemical biosensors, electrical 
leads/electrodes, therapeutic delivery systems, and orthopaedic and cardiovascular 
prostheses.2, 192-194  Extensive research has identified mechanisms governing acute 
inflammatory responses to implanted synthetic materials.  Adsorption of fibrinogen and 
complement fragments from plasma onto biomaterial surfaces results in integrin receptor-
mediated leukocyte recruitment and adhesion.52, 63, 65  Adherent monocytes/macrophages 
secrete cytokines and growth factors and mature into foreign body giant cells that 
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coordinate the recruitment and activities of other cell types,41, 85 leading to 
neovascularization and connective tissue formation.1  Despite our understanding of acute 
inflammation to implanted synthetic materials, mediators of chronic inflammation and 
fibrous encapsulation of implanted biomaterials remain poorly understood.   
Fibronectins (FNs) are widely expressed, cell-adhesive glycoproteins present as 
soluble forms in body fluids (e.g., plasma FN, pFN) and insoluble fibrils in extracellular 
matrices (cellular FN, cFN).195  FNs are generated from a single gene, but alternative 
splicing gives rise to different isoforms.195 Deletion of the FN gene is embryonically 
lethal due to defects in mesoderm, neural tube and vascular development.196  FN is also 
required for cleft formation during epithelial branching morphogenesis.197  Extensive in 
vitro analyses have demonstrated that FNs promote cell adhesion and regulate the 
survival, cell cycle progression, and expression of differentiated phenotypes in various 
cell types.  Despite the vast amounts of studies on the role of FN in cellular functions, the 
role of the pFN isoform in adult physiology and pathology has been difficult to analyze 
because of the embryonic lethality of the FN gene deletion.  Recent studies with FN 
conditional knock-out mice have shown that pFN promotes thrombus growth and 
stability in injured arterioles and supports neuronal survival following cerebral ischemia, 
but is not essential to skin-wound healing, likely due to contributions from cFN.198, 199  In 
the present analysis, we used pFN conditional knock-out mice to examine the 





MATERIALS AND METHODS  
pFN conditional knockout mice  
pFN conditional knock-out mice based on the Cre-loxP system were previously 
developed by Erickson and Fässler198 and rederived by Hynes.199  The Cre-loxP system 
provides a genetic tool to control site-specific recombination events in genomic DNA, 
thereby affording a mechanism for deleting a specific gene in response to a stimulus that 
results in Cre recombinase expression.  These mice have the FN gene flanked by loxP 
sites and express Cre recombinase under control of the interferon- and polyinosinic-
polycytidic acid (pI-pC)-inducible Mx promoter.  Deletion of the FN gene is induced by 
intraperitoneal injections of pI-pC and results in complete and stable deletion of FN in the 
liver (hepatocytes produce pFN) for at least eight months.198 Breeding pairs of mice 
containing a floxed (fl; loxP-site containing) fibronectin allele and Mx-Cre were kindly 
provided by H.P. Erickson and R.O. Hynes.  Floxed mice were crossed with Mx-Cre 
mice to generate FN (fl/fl) animals carrying the Mx-Cre transgene.  The presence of the 
transgene was verified by PCR of DNA extracted from tail tissue with Cre-specific 
primers. Deletion of the FN gene was induced in 8-12 week-old female mice by 3 
intraperitoneal injections of pI-pC (250 μg) at 2 day intervals.  Blood samples were 
drawn from the saphenous vein from intraperitoneal space at least 3 days following the 
last pI-pC injection to assess pFN levels by Western blotting using a rabbit polyclonal 
antibody against human fibronectin (Sigma; this antibody cross-reacts with mouse 
fibronectin).  Lavage from intraperitoneal space was obtained from animals at the time of 
disk explant. All experiments were conducted under IACUC-approved protocols. 
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Biomaterial implantation and analysis 
Discs (9.5 mm diameter, 0.5 mm thick) were cut from PET sheets, washed, and 
sterilized in ethanol.  Samples had endotoxin levels below the recommended maximum 
FDA level (0.5 EU/ml) as determined by the LAL chromogenic assay.  Discs were 
implanted either intraperitoneally (n = 8 samples/group) or subcutaneously (n = 4-5 
samples/group) following IACUC-approved procedures.  For intraperitoneal implants, 
discs were explanted at 16 hours.  Adherent cells were trypsinized and either analyzed in 
a Coulter counter (for total leukocyte cell counts) or fixed and stained with May-
Grunwald-Geimsa for differential cell counts in cytospins.  For subcutaneous implants, 
PET discs were explanted at 14 days, formalin-fixed and paraffin-embedded.  
Histological sections (5 μm thick) were stained with Verhoeff-van Geisson stain for 
nuclei (dark blue) and collagen (pink).  For immunohistochemical staining, sections were 
incubated in rabbit polyclonal antibody against fibronectin (Sigma, St. Louis, MO) or rat 
monoclonal antibody against the F4/80 antigen of resident murine tissue macrophages 
(clone BM8, Accurate Chemical & Scientific), biotinylated secondary antibodies, and an 
avidin-linked alkaline phosphatase-based reagent (Vector Labs, Burlingame, CA), and 
counterstained with hematoxylin.  For cell macrophage/FBGC counting, high 
magnification (60X oil objective) images were blindly scored for total nuclei, F4/80+ 
cells with one nucleus, and F4/80+ multinucleated cells. 
 
Statistical Analysis 
Results were analyzed by ANOVA using SYSTAT 8.0 (SPSS Inc., Chicago, IL).  
For macrophage/FBGC, a nested one-way ANOVA design (animal nested within 
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treatment) was used to account for the variance across subjects.200 Pair-wise comparisons 




We used pFN conditional knock-out mice based on the Cre-loxP system198, 199 to 
examine the role of pFN in host responses to implanted biomaterials.  Deletion of the FN 
gene in these mice is induced by intraperitoneal injections of pI-pC and results in 
complete and stable deletion of FN in the liver (hepatocytes produce pFN) for at least 
eight months.198  The extent of FN deletion in other tissues is variable, and some cell 
types retain the ability to produce cFN.  Importantly, these mice express normal levels of 
other extracellular matrix components such as collagen I, laminin-1, and tenascin.  
Following pI-pC induction, these mice exhibit less than 2% of pFN in normal mouse 
plasma (Figure 4.1a) and display no overt phenotype under standard laboratory 
conditions.  As expected, deletion of pFN also eliminated FN in the intraperitoneal fluid 
(Figure 4.1b).  We refer to these mice as pFN-null mice throughout this paper.  No 
differences between untreated (no pI-pC treatment) mice carrying the Mx-Cre transgene 
and pI-pC-treated wild-type littermates were observed in any assay, and we refer to these 







Figure 4.1: Levels of plasma fibronectin 
determined by Western blot analysis.  pI-pc 
induction effectively deletes FN from (a) plasma 
and (b) intraperitoneal fluid in mice carrying the 
Mx-Cre transgene (pFN-null) but not control (C) 
animals.  Western blot analysis with polyclonal 
antibody against fibronectin demonstrated 




 To investigate the role of pFN on leukocyte recruitment during the acute 
inflammatory response to biomaterials, polyethylene terephthalate (PET) discs were 
implanted in the intraperitoneal space for 16 hours and then explanted for analysis of 
leukocyte recruitment and adhesion.  This model has been extensively used to analyze 
leukocyte recruitment to biomaterials.64, 65, 201  PET is a widely used biomaterial which 
elicits a moderately strong inflammatory response.65  The knitted form of this material, 
Dacron®, is widely used in vascular grafts.  No differences were observed in total 
leukocyte counts of cells attached to implanted discs between pFN-null and control mice 
(p = 0.79) (Figure 4.2a).  Furthermore, differential cell counts revealed no differences in 
lymphocyte, neutrophil, and monocyte adhesion to PET discs between pFN-null and 
control mice (p = 0.19) (Figure 4.2b).  These results indicate that pFN does not play a 
major role in the recruitment and adhesion of leukocytes to implanted materials during 




Figure 4.2: Leukocyte adhesion to implanted biomaterials.  pFN does not 
influence acute leukocyte recruitment and adhesion to implanted biomaterials.  PET 
disks were implanted in the intraperitoneal cavity in mice with pFN deleted (pFN-
null) and control (C) animals.  No differences were observed in adherent (a) total or 




PET discs were also implanted subcutaneously for 14 days to assess the 
contributions of pFN to the foreign body reaction and fibrous encapsulation of implanted 
materials.  Measurement of fibrous capsule thickness following subcutaneous 
implantation is a standard measure of chronic inflammation to synthetic materials.1  PET 
discs implanted in pFN-null mice were encapsulated by thick, dense fibrous membranes 
(Figure 4.3a), while discs implanted in control animals exhibited considerably thinner 
capsules (Figure 4.3b).  Fibrous capsules were thicker on the implant side facing the 
dermis compared to the implant side facing the body wall as is often seen in this model, 
but the relative difference in capsule thickness between pFN-null and control animals was 
equivalent.  Measurements of capsule thickness indicated a 2-fold increase in fibrous 
capsule thickness for pFN-null mice compared to controls (dermis, p < 0.04; body wall, p 
< 0.02) (Figure 4.3c,d).  These results indicate that pFN modulates the foreign body 












Figure 4.3: Fibrous encapsulation of subcutaneously implanted biomaterials.  pFN 
modulates the foreign body reaction and fibrotic response to PET disks implanted 
subcutaneously for 14 days.  Verhoeff-van Geisson stained sections (collagen: pink; cell 
nuclei: dark blue) of tissue response to implanted biomaterials showing fibrous capsules 
(arrows) in (a) control (C) and (b) mice with deleted pFN (pFN-null).  Measurement of 
capsule thickness revealed thicker capsules around PET implants in pFN-null mice 
compared to controls (C) for both (c) body wall (p <0.02) and (d) dermis (p <0.04) faces 




To evaluate whether pFN is involved in macrophage recruitment and fusion into 
foreign body giant cells (FBGC), sections were stained for the F4/80 antigen (a marker of 
resident tissue macrophages) and scored for total nuclei, F4/80+ cells with one nucleus 
(macrophages), and F4/80+ cells containing multiple nuclei (FBGC).  More intense 
staining for the macrophage marker F4/80 antigen was observed for mice lacking pFN 
than control animals (Figure 4.4a,b).  A three-fold increase in the number of FBGC 
associated with the implant was detected in pFN-null mice compared to controls (p < 
0.04) (Figure 4.4c).  No differences were observed in the number of total cells (p = 0.40) 
or macrophages (p = 0.45).  This result suggests that pFN regulates the formation of 
biomaterial-associated FBGC. 
Immunohistochemical staining for FN showed intense staining localized to the 
fibrous capsule for both pFN-null and control animals (Figure 4.5).  FN was distributed 
throughout the dense fibrous capsule associated with the biomaterial.  Since the 
polyclonal antibody used recognizes both pFN and cFN, the staining most likely indicates 
the presence of cFN within the fibrous capsule.  As discussed above, for this conditional 
knock-out model, some tissues retain expression of cFN even though pFN is effectively 
deleted.198  Monocytes/macrophages and fibroblasts associated with the fibrous capsule 





















Figure 4.4: Biomaterial-associated macrophages and FBGC determined by 
immunohistochemistry.  Staining for macrophage marker F4/80 (pink) is more intense 
in pFN-null animals (b) compared to control mice (a).  Multinucleated F4/80+ cells are 
indicated by black arrowhead.  (c) Cell counts showing elevated biomaterial-associated 








Figure 4.5: Immunohistochemical staining 
for FN in fibrous capsules.  FN (arrows, dark 
pink) is localized at the tissue-material 
interface of encapsulated PET disks implanted 
subcutaneously in control (a) and pFN-null 




Our results demonstrate that pFN modulates the foreign body response and 
fibrous encapsulation of implanted materials.  This is the first report directly linking pFN 
to host inflammatory responses to implanted synthetic materials.  Deletion of pFN, 
however, did not influence leukocyte recruitment and adhesion to the implanted 
biomaterial, indicating that pFN regulates chronic, but not acute, inflammatory responses 
to biomaterials.  The lack of involvement of pFN in acute leukocyte adhesion to synthetic 
materials in vivo is consistent with other in vitro and in vivo analyses showing that 
fibrinogen is the major plasma component mediating leukocyte recruitment to 
biomaterials.65, 202  Unexpectedly, collagenous capsules surrounding implanted PET discs 
were twice as thick in pFN-null mice compared to wild-type mice.  This finding that 
collagen capsules are thicker in the absence of pFN is surprising given the requirement of 
FN on collagen assembly.203, 204  This result indicates that pFN is involved in the 
deposition and/or remodeling of the fibrous capsule surrounding implanted materials.  
The mechanism(s) by which pFN regulates fibrous capsule thickness remains unclear, but 
pFN may modulate host responses by adsorbing directly onto the material or by 
interacting with other proteins associated with the biomaterial, such as fibrinogen and 
collagen.  pFN associated with the biomaterial may influence the adhesion and/or 
function of cells involved in the foreign body reaction, including the ability to assemble 
and remodel the collagenous capsule or secrete cytokines regulating fibrosis.  Indeed, we 
observed a significant increase in the number of FBGC associated with the implant in 
pFN-null compared to control mice.  This result suggests that pFN regulates the 
formation or maturation of FBGC.  This model is consistent with in vitro findings 
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implicating fibronectin-binding β1 integrins and fibronectin-derived binding motifs in 
FBGC fusion and maturation.41, 205  Moreover, Horbett and colleagues demonstrated that 
monocyte adhesion to adsorbed fibronectin reduced FBGC formation.13 
Interestingly, considerable levels of FN, corresponding to cFN, were present on 
the capsules of both pFN-null and control mice.  This observation suggests that the 
differences in fibrous capsule thickness are specific to pFN, and cFN cannot compensate 
for the loss of pFN.  There is evidence that different isoforms of FN support cell adhesion 
and migration to different extents.206-209  Finally, host responses to implanted materials 
are often interpreted in the context of classical wound healing.  However, the important 
role of pFN in the inflammatory response and foreign body reaction observed in our 
study contrasts with the ability of skin wounds to heal normally in the absence of pFN in 
the same animal model.198  These results highlight inherent differences between classical 
wound healing and host responses to implanted materials.  
 The use of a conditional knock-out model provides a robust system to evaluate the 
role of specific proteins in host responses to implanted materials in adult animals without 
complicating compensatory effects associated with conventional knock-out models.  For 
example, Bornstein and colleagues demonstrated that mice lacking the angiogenesis 
inhibitor thrombospondin 2 mount an altered foreign body reaction to implanted 
materials characterized by increased capsule thickness and vascularity.210  However, 
interpretation of the results is complicated by the fact that these mice exhibit connective 
tissue abnormalities, including disordered collagen fibrillogenesis and vascular density.211   
Our results identify a potential target for therapeutic intervention to enhance the 
biological performance of biomedical devices.  Control of pFN activity via drug-, 
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protein-, or gene-based manipulations of plasma concentration, availability, or 
presentation on the material could be exploited to manipulate host responses.  For 
instance, we have shown that biomaterial surface chemistry-dependent changes in the 
activity of adsorbed FN modulate integrin receptor binding and cell differentiation 
responses.212  Moreover, biomaterial-based strategies focusing on presenting FN or FN-
derived adhesion motifs enhance host integration and function in model systems, 
including bone and cartilage.213-215  These enhancements are attributed to improved 
interactions with the host target tissue (e.g. bone) rather than altered inflammatory 
responses.  Our results support pFN-mediated regulation of the foreign body reaction and 
chronic inflammatory responses as a new mechanism for controlling host responses to 
synthetic biomedical materials.   
 
CONCLUSION 
Using plasma fibronectin conditional knock-out mice, we demonstrate that plasma 
fibronectin modulates the foreign body response to biomaterial discs implanted 
subcutaneously.  Fibrous collagenous capsules were two-fold thicker and three-fold 
higher numbers of foreign body giant cells were observed in mice depleted of plasma 
fibronectin compared to controls.  In contrast, deletion of plasma fibronectin did not alter 
acute leukocyte recruitment to the biomaterial, indicating that plasma fibronectin 
modulates chronic fibrotic responses.  These results implicate plasma fibronectin in the 
host response to implanted materials and identify a potential target for therapeutic 
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Host inflammatory responses to implanted biomaterials limit device integration 
and biological performance for most classes of medical devices, including chemical 
biosensors, leads and electrodes for monitoring and/or stimulation, drug delivery systems, 
and orthopaedic implants.15  These inflammatory responses to synthetic materials involve 
dynamic, multi-component and inter-dependent reactions comprising biomolecule (e.g., 
protein) adsorption, leukocyte recruitment, adhesion and activation, cytokine 
expression/release, macrophage fusion into multi-nucleated foreign body giant cells, 
tissue remodeling and fibrous encapsulation.15, 191  The duration and intensity of these 
stages is dependent upon the extent of injury created at the implantation site and the 
biomaterial physicochemical properties.15  
Significant biomaterial-based efforts have focused on engineering implant surface 
coatings to attenuate host inflammatory responses to implanted devices.  Strategies 
focusing on the presentation/delivery of anti-inflammatory and/or pro-wound healing 
agents, such as heparin, dexamethasone, and superoxide dismutase mimetics, have 
demonstrated promising reductions in inflammatory responses and fibrous 
encapsulation.161, 177, 216  These approaches, however, are limited by complex delivery 
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pharmacokinetics.  For example, Reichert and colleagues demonstrated that combined 
release of dexamethasone and vascular endothelial growth factor reduced fibrous capsule 
thickness without changes in vascularization around implanted devices.161  However, 
these benefits were lost at longer implantation times, possibly due to reductions in the 
release of bioactive agents.  In addition to these bioactive approaches, non-fouling (i.e. 
protein adsorption-resistant) coatings, including dense polymeric films and brushes as 
well as hydrogels have been pursued to modulate inflammatory responses to implanted 
materials.147, 149, 188, 217-219, 220, 221, 222, 223  The rationale for these passive approaches is that 
reduction in protein adsorption will lead to reduced leukocyte adhesion and activation, 
thereby attenuating the extent of the foreign body reaction.  Although many of these 
coatings exhibit reduced protein adsorption and leukocyte adhesion/activation in vitro, 
inconsistent results have been obtained regarding the ability of these materials to reduce 
in vivo acute and chronic inflammatory responses.147, 188, 221, 224  Possible explanations for 
the mixed in vivo results with these coatings include insufficient non-fouling behavior, 
coating degradation, and inflammatory mechanism(s) independent from protein 
adsorption. 
Micro- and nano-structured hydrogels offer distinct advantages over traditional 
surface modifications, including high water content, high diffusivity for solute transport 
within polymer network, and the ability to incorporate multiple chemical functionalities 
to generate complex architectures.38, 225  We recently developed a biomaterial coating 
strategy based on films of microgel particles of poly(N-isopropylacrylamide) (pNIPAm) 
cross-linked with short chains of non-fouling poly(ethylene glycol) (PEG) that render 
glass and polymeric substrates resistant to fibroblast adhesion in vitro.89  The objective of 
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the present study was to evaluate in vitro and in vivo inflammatory cell responses to these 
microgel films tethered onto poly(ethylene terephthalate) (PET).  PET was chosen as the 
base material because this polymer is used in many biomedical devices, including 
sutures, vascular grafts, sewing cuffs for heart valves, and components for percutaneous 
access devices. PET elicits acute and chronic inflammatory responses characterized by 
leukocyte adhesion and fibrous encapsulation.65, 226  Furthermore, PET has been used a 
model biomaterial for numerous basic biomaterial-host interactions.  We demonstrate that 
these microgel conformal coatings reduce in vitro monocyte/macrophage adhesion and 
spreading as well as leukocyte recruitment, adhesion, and pro-inflammatory cytokine 
expression to implanted PET in an in vivo acute inflammation model. 
 
MATERIALS AND METHODS 
Sample preparation 
Thin sheets of PET (AIN Plastics/ThyssenKrupp Materials NA, Madison Heights, 
MI) were cut into disks (8 mm diameter) using a sterile biopsy punch (Miltex Inc., York, 
PA) and rinsed briefly in 70% ethanol to remove contaminants introduced during the 
manufacturing process.  pNIPAm microgel particles (100 mM total monomer 
concentration) were synthesized with 2 mol% PEG diacrylate (MW 575) by free radical 
precipitation polymerization.89  Particles were synthesized with 10 mol% acrylic acid as a 
co-monomer to incorporate functional groups for future modification.  Particle 
composition was confirmed by NMR.  Particle size (hydrodynamic radius) and 
polydispersity were 334 ± 30 nm and 1.11 + 0.03, respectively.  Microgels were 
deposited on the surface of PET disks using a spin coating process as previously 
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described.122  All samples were rinsed in 70% ethanol on a rocker plate for 4 days, 
changing the solution daily to clean the samples and remove endotoxin contaminates.  
Prior to use, samples were rinsed three times in sterile phosphate buffered saline (PBS) 
and allowed to rehydrate for at least 1 h.  Samples contained 10-fold lower levels of 
endotoxin than the United States Food and Drug Administration’s recommended 0.5 
EU/mL, as determined by the LAL chromogenic assay (Cambrex, East Rutherford, NJ). 
 
Biomaterial surface characterization 
X-ray photoelectron spectroscopy (XPS) analysis was performed on a Surface 
Science SSX-100 small spot ESCA Spectrometer using monochromatic Al K alpha X-
rays, 800 μm spot size, 150 eV pass energy, and take-off angle of 55°.  Atomic force 
microscopy (AFM) images were obtained in AC mode on an Asylum Research MFP-3D 
atomic force microscope.  Spring constants were calculated using the thermal method.  
Imaging and analysis was performed using the Asylum Research MFP-3D software 
(written in the IgorPro environment, WaveMetrics, Inc., Lake Oswego, OR).  An 
Olympus AC160 cantilever with k = 42 N/m, f0 = 300 kHz was used for imaging. 
 
Fibrinogen adsorption 
Fibrinogen was selected as a model plasma protein to quantify protein adsorption 
onto biomaterial surfaces.  The amount of surface-adsorbed protein was determined using 
a purified solution of radiolabeled fibrinogen diluted with unlabeled fibrinogen.  Samples 
were incubated for 1 h in a mixture of 125I-labeled human fibrinogen (65% purity, 95% 
clottable, specific activity of 0.86 μCi/μg, MP Biomedicals, Irvine, CA) and unlabeled 
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human fibrinogen (65% purity, 95% clottable, Sigma-Aldrich, St. Louis, MO) to generate 
a range (2-200 μg/mL) of coating concentrations.  Tri(ethylene glycol)-terminated self-
assembled monolayers on gold-coated glass coverslips and unmodified glass coverslips 
were used as controls.  Following incubation in fibrinogen solutions, samples were rinsed 
in PBS, incubated for 30 min in a 1% solution of heat-denatured bovine serum albumin 
(BSA), and rinsed in PBS to remove loosely adsorbed proteins.  A Packard Cobra II 
gamma counter was used to measure the level of radiolabeled fibrinogen adsorbed onto 
the samples.  After correcting for background and label dilution, the amount of protein 
adsorbed on each sample was calculated as the radioactive counts divided by the surface 
area and specific activity.  Pilot experiments demonstrated that the albumin incubation 
and buffer rinses only displace a small amount (< 10%) of adsorbed fibrinogen from 
these surfaces. 
 
Primary human monocyte isolation and culture 
Peripheral human whole blood was obtained from healthy volunteer donors at the 
Georgia Institute of Technology Student Health Center in accordance with an approved 
Institute Review Board protocol (H05012).  To prepare autologous human serum, blood 
(120 mL) was centrifuged (3000 rpm, 10 min, room temperature) to pellet red blood 
cells. The supernatant was collected, pushing down clots manually using a sterile pipette 
tip, and allowing further clotting (90 min, room temperature) with clearance by another 
centrifugation (3000 rpm, 15 minutes, room temperature).    
Human monocytes were isolated from whole blood immediately after collection 
using an established method developed by Anderson’s group63, 85 with slight 
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modifications.  Cell isolations were performed on blood from three separate donors for 
three independent experiments (unpooled samples) with equivalent results.  Blood (120 
mL) was collected in heparin-coated syringes (333 U/mL blood, Baxter Healthcare, 
Deerfield, IL).  The heparinized blood was transferred to polystyrene bottles (Corning, 
Corning, NY), diluted 1:1 with sterile PBS without calcium/magnesium, and gently 
swirled to mix.  Peripheral blood mononuclear cells were separated using lymphocyte 
separation medium (Cellgro MediaTech, Herndon, VA) by differential gradient 
centrifugation (400g, 30 min at room temperature in a Thermo Fisher centrifuge, model # 
5682, rotor IEC 216). The mononuclear cell layer was collected and erythrocytes lysed 
(155 mM ammonium chloride, 10 mM potassium bicarbonate and 0.1 mM EDTA) and 
washed twice with sterile PBS to remove the lysis buffer.  This isolation procedure 
yielded > 95% viable cells as determined by Trypan blue exclusion.  Flow cytometric 
analyses indicated 50 ± 5% monocytes (CD14+) and 46 ± 3% lymphocytes (CD14-).  
These yields for cell viability and monocyte fractions are consistent with previous 
reports.63, 202 
Cells were resuspended at a concentration of 5 x 106 cells/mL in culture media 
(RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine (Invitrogen), 100 U/mL 
penicillin/streptomycin (Cellgro) and 25% filter-sterilized autologous human serum), 
plated in a volume of 10 mL onto 100-mm Primaria™ culture plates, and incubated at 37 
°C and 5% CO2.  After 2 h, non-adherent cells were removed by rinsing three times with 
warm media.  Cells were cultured for 10 days prior to plating onto experimental/control 
surfaces based on previous results showing that this time period provides for sufficient 
macrophage maturation.85  Media changes occurred on days 3 and 6 of culture with 
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media containing heat-inactivated autologous serum (56 °C, 1 h) used on day 6.  By day 
10 in culture, this procedure yielded 61 ± 18% macrophages (CD64+) and 29 ± 18% 
lymphocytes.  The purity of macrophages increases with time in culture as non-adherent 
lymphocytes are washed away.  We note that there is evidence that lymphocytes 
modulate and support monocyte differentiation as well as monocyte activities on 
biomaterials,88 suggesting that it is relevant to include this lymphocyte population in 
culture.  
 
In vitro murine and human macrophage adhesion  
Murine IC-21 macrophages (TIB-186, ATCC, Manassas, VA) were plated at a 
density of 67,000 cells/cm2 on unmodified PET controls and microgel-coated samples.  
IC-21 cells were maintained in RPMI-1640 containing 25 mM HEPES, 2 mM L-
glutamine, 100 U/mL penicillin/streptomycin and 10% fetal bovine serum at 37 °C and 
5% CO2.  Human monocytes were plated at 50,000 cells/cm2 on microgel-coated PET or 
unmodified PET controls and maintained in culture media supplemented with 25% 
autologous human serum at 37 °C and 5% CO2.  Following 48 h of culture, biomaterial 
samples were rinsed three times with sterile PBS to remove loosely adherent cells.  
Remaining adherent cells were stained with calcein-AM (live cells) and ethidium 
homodimer-1 (dead cells) (Invitrogen) and imaged using a Nikon E-400 microscope 
equipped with epifluorescence optics and image analysis.  Five representative fields per 
sample (4-5 independent samples per condition) were acquired (10X Plan Fluor Nikon 
objective, 0.30 NA), and image analysis software (ImagePro, Media Cybernetics, Silver 
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Spring, MD) with in-house macros was used to count adherent cells and quantify cell 
spreading.   
 
Murine intraperitoneal implantation 
An established intraperitoneal implantation model was used to assess acute 
inflammatory responses.52, 65  Animal procedures were conducted in accordance with an 
IACUC-approved protocol.  Male 10-14 wk old C57BL/6 mice (Charles River 
Laboratories, Wilmington, MA) were anesthetized by isofluorane.  Following a midline 
incision into the peritoneal cavity, sterile samples (two disks per mouse) were implanted 
for 48 h.  Sham surgeries were performed on additional mice to be used as controls.  Prior 
to explantation, the IP cavity was injected with 3 mL of sterile PBS containing sodium 
heparin (50 U/mL, Baxter Healthcare, Deerfield, IL) as an anticoagulant.  The abdomen 
was then massaged briefly, the IP lavage fluid was collected using a syringe, and disks 
were retrieved for analysis.  One disk was used for immunofluorescence staining of 
adherent cells, and the second disk was used to harvest adherent cells for flow cytometric 
analysis of intracellular cytokine levels.  Animals were sacrificed using a CO2 chamber. 
 
Immunofluorescence staining of adherent cells 
Following careful explantation from the intraperitoneal cavity, biomaterial disks 
were stored briefly in PBS until completion of the retrieval surgery.  Samples were then 
rinsed three times in PBS and fixed with 10% neutral buffered formalin.  Adherent cells 
were permeabilized using 0.1% Triton-X 100 in PBS.  Fetal bovine serum (5%) in PBS 
was used to block non-specific protein binding.  Explants were then incubated at room 
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temperature with a primary monoclonal antibody against the macrophage marker CD68 
at a 1:200 dilution (clone KP1, Abcam, Cambridge, MA).  After rinsing to remove excess 
antibody, explants were incubated in AlexaFluor 488-conjugated goat anti-mouse IgG 
antibody (1:200 dilution) and counterstained with rhodamine-phalloidin (1:100 dilution) 
and Hoechst (1:10,000 dilution) to stain actin filaments and nuclei, respectively.  Isotype 
control antibodies and additional staining controls demonstrated specific staining of 
target epitopes with minimal background.  Antibodies were diluted in a solution of 1% 
heat-denatured BSA in PBS, and all reagents were used at 4 °C.  Samples were then 
rinsed five times in PBS and once in deionized H2O, mounted on glass slides with 
coverslips, and stored in the dark at 4 °C until imaged.  Eight fields per sample were 
acquired (20X Plan Fluor Nikon objective, 0.45 NA), and ImagePro software (Media 
Cybernetics, Silver Spring, MD) with custom-designed macros was used to count the 
adherent cells.  Results shown represent 5 or more animals per treatment group from a 
single implantation experiment. 
 
Intracellular cytokine staining and flow cytometric analysis 
The second disk explanted from the intraperitoneal cavity was used for 
measurements of cytokine expression in implant-associated cells via flow cytometry.  
Explanted samples were rinsed briefly in PBS and quickly transferred to a 24-well plate, 
and lavage samples were centrifuged to pellet cells.  Cytokine staining was performed 
using fluorophore-labeled antibodies according to the manufacturer’s protocol 
(eBioscience, San Diego, CA).  Briefly, 1.0 mL of warm brefeldin A solution (3 μg/mL) 
in serum-containing media was added to each sample (disk or lavage fluid) to inhibit 
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protein secretion into the media, and cells were incubated for 4 h at 37 °C to allow for 
cytokine accumulation within the cells.   
Pilot experiments with different dissociation conditions were performed to 
identify protocols to efficiently isolate implant-associated cells with minimal cellular 
debris and appropriate staining and instrument settings for flow cytometry analysis.  For 
cell harvest, samples were rinsed three times in cold PBS without calcium/magnesium.  
Disk-adherent cells were removed using warm trypsin (0.05% containing 0.53 mM 
EDTA), transferred to microcentrifuge tubes, and centrifuged at 300g.  The resultant cell 
pellet was resuspended in 1.0 mL of 10% neutral buffered formalin, and tubes were 
shaken at low speed on a vortexer for 10 min.  A series of rinse-and-centrifuge cycles 
were used to remove excess fixative, and cell pellets were resuspended in a combined 
permeabilization/blocking buffer and replaced on the vortexer for 20 min.  Fluorophore-
conjugated antibodies (APC-conjugated anti-mouse TNF-α (clone MP6-XT22), FITC-
labeled anti-mouse IL-1β polyclonal antibody, PE anti-mouse MCP-1 (clone 2H5), FITC-
labeled anti-mouse IL-10 polyclonal antibody, eBioscience) were added to the 
microcentrifuge tubes at the manufacturer’s recommended dilutions and shaken in the 
dark for 1 h.  A subset of samples were stained using macrophage- and neutrophil-
specific markers (PE-conjugated anti-mouse F4/80 (clone BM8) and APC-labeled anti-
mouse Gr1 (clone RB6-8C5) from eBioscience and Miltenyi Biotec, Auburn, CA) to 
label and identify the cell populations of interest.  Cells were then subjected to another 
series of rinse-and-centrifuge cycles to remove excess antibody and resuspended in PBS.  
A Becton Dickinson BD LSR digital flow cytometer was used to measure the 
fluorescently-labeled intracellular cytokines (counting 10,000 events per sample), and 
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FlowJo software v7.2 (Tree Star Inc., Ashland, OR) was used to analyze the data.  




Data are presented as mean ± standard error.  Statistical analysis was performed 
by ANOVA using Systat 11.0 (Systat Software Inc., San Jose, CA).  Flow cytometry 
histograms were compared using the Kruskal-Wallis non-parametric test. Pair-wise 
comparisons were performed using Tukey post-hoc tests with a 95% confidence level 
considered significant.   
 
RESULTS 
Deposition of microgel particles as conformal coatings 
PET substrates (Figure 5.1a) were functionalized with p(NIPAM-co-AAc-co-
PEGDA) microgel particles (Figure 5.1b and c), which were covalently attached to the 
surface via the incorporation of an aminobenzophenone photoaffinity label followed by 
UV excitation to form a covalently cross-linked coating122 (Figure 5.1).  Biomaterial 
surfaces were analyzed for both chemical composition and the uniformity of microgel 
deposition using XPS and AFM, respectively.  XPS survey scans revealed the presence of 
carbon and oxygen groups on unmodified PET controls and microgel-coated surfaces 
(Figure 5.1d and e, respectively).  Nitrogen groups (400 eV binding energy) were 
present only on microgel-coated surfaces (Figure 5.1e).  With respect to elemental 
composition, PET substrates contained approximately 72% carbon and 25% oxygen, 
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whereas microgel coatings contained 77% carbon, 15% oxygen, and 9% nitrogen (all 1s 
orbitals).  Additional high resolution scans confirmed multiple carbon bonds 
corresponding to the chemical structures of the PET substrate and microgel coatings 
(Figure 5.1f and g, respectively).  In particular, there was an abundance of amide bonds 
characteristic of pNIPAm in the microgel coating.  This chemical composition is 
consistent with the theoretical values. 
AFM images were obtained and rendered in three dimensions (Figure 5.2) to 
visualize surface topography of the biomaterials.  PET displayed a generally smooth 
surface (< 200 nm) exhibiting scratches and surface defects (Figure 5.2a), most likely 
arising from the manufacturing process.  Spin coating-based deposition of the microgel 
particles resulted in a conformal coating on the surface with microgel particles effectively 
filling in scratches and covering ridges commonly present on the surface of the 
underlying PET substrate (Figure 5.2b).  The thickness of these microgel coatings is on 
average 160 nm (dry) and 300 nm (swollen), as determined by AFM.  Comparisons 
between AFM analyses of substrates with incomplete and full microgel coverage 
indicated monolayer particle deposition, with no evidence of multilayer formation.  More 
expansive 50 x 50 µm2 scans also confirmed uniform microgel coverage (results not 
shown).  The presence of these pNIPAm-specific nitrogen groups, along with AFM 
image analysis, confirms that the microgel particles were successfully deposited on the 
surface of PET disks.    




Figure 5.1: Surface characterization of biomaterials.  Chemical structures of the 
unmodified PET (a) and p(NIPAM-co-AAc-co-PEGDA) microgel particles (b) are 
shown for reference.  (c) Microgel particles (red spheres) are covalently attached to the 
surface of the underlying PET substrate (gray disk) by photo-crosslinking to create a 
polymeric coating.  XPS analysis reveals the presence of nitrogen groups characteristic of 
C-N bonds on the surface of microgel-coated PET (e) that are absent in unmodified PET 
controls (d).  High resolution carbon 1s data was deconvoluted, and software was used to 
assign peak values and determine individual carbon bonds.  Results are shown for 
unmodified PET (f) and microgel-coated PET (g).  Importantly, microgel coatings 
contain C-N bonds, characteristic of the amide groups in the pNIPAm particles. 
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Figure 5.2: Topography of biomaterial surfaces.  Representative 3D 
renderings of atomic force microscopy images demonstrate that the 
functionalization strategy yields a conformal coating of microgel particles 




Fibrinogen adsorption studies 
We next examined the ability of these microgel coatings to attenuate protein 
adsorption.  Fibrinogen was selected as the model protein for adsorption studies as this 
plasma component has been extensively studied in the context of host responses to 
synthetic materials.  In addition to playing a central role in platelet adhesion to blood-
contacting materials, fibrinogen adsorption promotes in vitro and in vivo leukocyte 
recruitment and adhesion to biomedical materials.52, 65, 202  Protein adsorption onto the 
surfaces was measured using 125I-labeled human fibrinogen from a purified solution 
(Figure 5.3).  Microgel-coated samples adsorbed 7-fold lower levels of fibrinogen 
compared to unmodified PET disks.  Additionally, the PEG-based microgel coatings 
performed comparably to tri(ethylene glycol)-terminated self-assembled monolayers 
(EG3 SAMs) on gold-coated glass substrates, which have been extensively examined as 
model non-fouling surfaces.30  Moreover, we previously demonstrated that microgel 
coatings reduce albumin adsorption to background levels.89  Taken together, these results 
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demonstrate that microgel-based coatings significantly reduce protein adsorption onto the 





Figure 5.3: Protein adsorption profiles on 
biomaterial surfaces.  Microgel-coated surfaces 
adsorb 7-fold lower levels of purified human 
fibrinogen than unmodified PET controls and 
also display comparable biofouling resistance to 
tri(ethylene glycol)-terminated self-assembled 




In vitro leukocyte adhesion 
We evaluated in vitro monocyte/macrophage adhesion to microgel-coated and 
unmodified PET as a model of the leukocyte recruitment/adhesion events in the acute 
phase of biomaterial-induced inflammation.  Murine IC-21 macrophages were plated and 
cultured for 48 h on biomaterials, and adherent cells were imaged and scored for 
viability, adherent cell density, and spread area.  Unmodified PET control samples 
supported significant levels of cell adhesion, whereas microgel coatings exhibited 40-fold 
lower levels of IC-21 macrophage adhesion (Figures 5.4a and b, respectively), as 
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quantified in Figure 5.4c (p < 1.2x10-5).  Furthermore, cells adherent to unmodified PET 
samples had almost double the cytoplasmic spread area of those associated with 
microgel-coated samples (Figure 5.4d, p < 1.2x10-5).  Calcein-AM/ethidium homodimer 
(Live/Dead™) staining showed > 98% viability for both surfaces. 
We performed similar studies with primary human monocytes/macrophages 
isolated from whole blood, as these primary cells represent a more clinically relevant 
model.15  After 48 h in culture with biomaterial surfaces, adherent cells were imaged and 
scored for viability, adherent cell density, and spreading area.  In good agreement with 
the murine macrophage line results, unmodified PET supported high numbers of adherent 
primary monocytes (Figure 5.5a), whereas microgel coatings (Figure 5.5b) reduced 
primary human monocyte/macrophage adherent cell numbers by 3-fold compared to 
control substrates.  These results are shown graphically in Figure 5.5c (p < 1.1x10-4).  In 
addition, cells adherent to unmodified PET control surfaces exhibited more cell 
extensions and had double the cytoplasmic spread area of those associated with microgel-
coated samples (Figure 5.5d, p < 1.2 x 10-5).  Calcein-AM/ethidium homodimer staining 
showed > 95% viability for both substrates.  These results demonstrate that microgel 
coatings significantly reduce monocyte/macrophage adhesion and spreading compared to 










Figure 5.4: Murine IC-21 macrophage adhesion to biomaterial surfaces.  Adherent 
cells were scored for viability, and cell density and area were quantified.  Compared to 
unmodified PET substrates (a), microgel coatings (b) reduce macrophage adhesion to 
biomaterial surfaces.  (c) Unmodified PET supported 40-fold higher levels of adherent 
macrophages compared to microgel-coated samples, which virtually eliminated cell 
adhesion, * p < 1.2x10-5.  (d) Adherent macrophages also exhibited more cell extensions 
and significantly larger surface areas on unmodified PET controls than on microgel-
coated surfaces, * p < 1.2x10-5.  Data is presented as the average value ± standard error of 














Figure 5.5: In vitro human primary macrophage adhesion to biomaterial surfaces.  
Adherent cells were scored for viability, and cell density and spread area were quantified.  
Compared to unmodified PET substrates (a), microgel coatings (b) reduce macrophage 
adhesion to biomaterial surfaces.  (c) Microgel coatings elicit a 3-fold reduction in cell 
adhesion compared to unmodified PET surfaces, * p < 1.1x10-4.  (d) Adherent 
macrophages also exhibit more cell extensions and 2-fold larger surface areas on 
unmodified PET controls than on microgel-coated surfaces, * p < 9.5x10-7.  Data is 
presented as the average value ± standard error of the mean using n = 5 samples per 
treatment group.  Scale bar is 100 µm. 
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Acute inflammatory cell responses to microgel coatings 
We next evaluated early cellular responses to biomaterials implanted in the 
intraperitoneal cavity of mice.  Tang and colleagues have established this model to 
examine leukocyte recruitment to implanted biomaterials during the acute inflammatory 
process.52, 65  Unmodified and microgel-coated PET disks (2 samples per mouse) were 
implanted for 48 h and then explanted and analyzed to determine leukocyte recruitment 
and adhesion as well as pro-inflammatory cytokine expression.  Mice surgically treated 
but not receiving any biomaterial disks were used as sham controls.   
One disk explanted from each mouse was used to examine leukocyte recruitment 
and adhesion by cell staining and fluorescence microscopy.  Following fixation and 
permeabilization, adherent cells were stained using an antibody against CD68 
(macrophage marker), rhodamine phalloidin (actin filaments), and Hoechst (nuclei).  
Unmodified PET control samples displayed a dense monolayer of adherent cells (Figure 
5.6a).  In contrast, significantly fewer cells were attached to the microgel-coated samples 
(Figure 5.6b).  Quantification of adherent cells demonstrated a 4.6-fold reduction in cell 
density for microgel-coated samples compared to unmodified PET (p < 1.1x10-5, Figure 
5.6e).  Furthermore, higher magnification images demonstrated fewer CD68+ 
macrophages on microgel-coated samples (Figure 5.6d) compared to unmodified PET 
controls (Figure 5.6c).  Similar results in terms of differences in adherent cell numbers 
between microgel-coated and unmodified PET surfaces were observed for in a small 




Figure 5.6: In vivo leukocyte adhesion to implanted biomaterials.  Biomaterial disks 
were implanted in the murine peritoneal cavity for 48 h. Explants were immunostained 
for macrophage marker CD68 (green), actin (red), and DNA (blue).  Representative 
images taken with 20X (a, b) and 40X (c, d) objectives are presented.  In contrast to 
unmodified PET controls (a), microgel-coated disks (b) effectively reduced leukocyte 
adhesion on these implants by a factor greater than 4-fold as quantified in (e), * p < 
1.1x10-5.  In addition, fewer macrophages were observed on microgel-coated (d) surfaces 
than on unmodified PET controls (c).  Data is represented as the average value ± standard 
error of the mean using n = 5 or more samples per treatment group.  Scale bar is 50 µm. 
 66
We also examined the expression of inflammatory cytokines (TNF-α, IL-1β, 
MCP-1, and IL-10) in implant-associated cells at 48 h of implantation by flow cytometry 
as a measure of leukocyte activation.  This cytokine profile was selected based on 
previous reports of acute cytokine expression around biomaterial implants.111, 227, 228, 229  
To ensure that the flow cytometry analysis was performed on whole cells and not debris 
for the harvest procedure, we first stained a subset of the harvested samples for markers 
characteristic of the cell populations, mainly macrophages and neutrophils.  Figure 5.7a 
shows a contour profile for forward scatter (FSC, proportional to particle size) vs. side 
scatter (SSC, proportional to antibody staining).  The profile was gated for two major 
areas (P1, P2).  The cell population in P1, which corresponds to 85-90% of the total 
number of events recorded, contains particles that (i) are large enough to represent whole 
cells (based on FSC values) and (ii) stain positive for macrophages and neutrophils.  We 
therefore performed analyses for cytokine expression on this P1 cell population.  This 
type of analysis is consistent with standard immunology flow cytometric analysis.230     
Figures 5.7b-d present histograms showing cell counts (y-axis) as a function of 
cytokine staining intensity (x-axis).  For TNF-α, IL-1β, and MCP-1, the histograms for 
microgel-coated PET show a left-ward shift compared to the histograms for untreated 
PET.  Kruskal-Wallis non-parametric tests indicated that the histograms for microgel-
coated PET were statistically different from histograms for control PET (p < 0.02).  In 
addition, ANOVA of the geometric means for histograms from independent samples 
showed that microgel-coated samples contained significantly lower levels of pro-
inflammatory TNF-α, IL-1β, and MCP-1 than unmodified PET controls (Figure 5.7e-g, 
respectively; p < 0.003).  No significant differences were detected between groups for 
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levels of anti-inflammatory IL-10 (results not shown).  Additionally, a peritoneal lavage 
was performed to collect fluid in the tissue exudates proximal to the implant.  No 
differences were detected between surface treatments for pro-inflammatory cytokine 
expression of cells in the exudate, and these levels of cytokine expression were similar to 
the sham controls.  These results demonstrate that leukocyte activation was dependent on 
adhesion to the biomaterial implant.  Furthermore, microgel coatings attenuate leukocyte 
activation and significantly reduce expression of pro-inflammatory cytokines compared 
to PET substrates. 
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Figure 5.7: Quantification of in vivo intracellular cytokine expression by flow 
cytometric analysis.  Disk-associated cells were harvested from implants and stained 
intracellularly for various cytokines, and several samples were stained for macrophage- 
or neutrophil-specific extracellular markers.  (a) Two main populations of cells (P1 and 
P2) were observed on FSC vs. SSC plots.  Macrophage and neutrophil populations of 
interest were both contained within P1, so cytometry profiles were gated using P1 for all 
subsequent data analysis.  (b, c, d) Representative histograms show a significant 
population shift between unmodified PET controls and microgel-coated PET for the three 
cytokines examined.  (e, f, g) Cells adherent to unmodified PET samples contained 
significantly higher levels of intracellular TNF-α (e), IL-1β (f), and MCP-1 (g) than 
microgel-coated samples, * p < 0.003.  Data is presented as the unbiased geometric 
means of the populations ± standard error of the mean using n = 4 or more samples per 
treatment group.   
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DISCUSSION 
 We present a coating strategy based on thin films of poly(N-isopropylacrylamide-
co-acrylic acid) hydrogel microparticles cross-linked with PEG diacrylate.  These 
microgel particles were spin-coated and covalently grafted onto PET substrates.  XPS and 
AFM analyses demonstrated that these particles were deposited as dense conformal 
coatings.  Attractive features of this coating technology include (i) precise control over 
particle synthesis in terms of composition and structure, (ii) ability to generate complex 
architectures and/or functionalities, including controlled drug release, and (iii) ability to 
generate “mosaic” complex coatings containing variations in particle composition and/or 
spatial arrangement via modular assembly and soft lithography.38  In addition, these 
particles can be deposited onto different substrates by various means, including spin 
coating, centrifugation, and dip-coating.  We note that the amount of mass attached with 
just a few chemical reactions at the surface is potentially extraordinarily high, which 
should be beneficial for obtaining high densities of PEG and good surface coverage.  
Compared to many “grafting-to” and surface polymerization reactions, this approach 
provides a more controllable route.  Nevertheless, generation of dense, conformal 
microgel coatings requires optimization of particle deposition parameters, including 
covalent tethering, and may not be easily applicable to surfaces with complex 
geometries/topographies.  
We examined in vitro protein adsorption onto microgel-coated and uncoated PET 
using radiolabeled fibrinogen as a model plasma protein.  Microgel coatings significantly 
reduced fibrinogen adsorption compared to unmodified PET.  Additionally, the PEG-
based microgel coatings performed equivalently to self-assembled monolayers presenting 
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tri(ethylene glycol).  The significant reductions in adsorbed fibrinogen for microgel 
coatings are in good agreement with previous results for low adsorption of serum 
albumin to these films.89  We attribute the reductions in protein adsorption to microgel 
coatings to the presentation of PEG ‘loops’ at the microgel surface resulting from 
temperature-induced deswelling of pNIPAm at physiological temperatures.89, 231  The 
levels of fibrinogen adsorbed onto microgel coatings (60 ng/cm2 at 30 µg/mL coating 
concentration) are comparable to protein densities (40-60 ng/cm2) adsorbed onto 
PEG/PEO polymers grafted onto surfaces.232, 233  However, the density of fibrinogen 
adsorbed onto the microgel coatings is considerably higher than protein densities (< 10 
ng/cm2) adsorbed onto dense brushes of oligo(ethylene glycol)methacrylate and poly(2-
methacryloyloxyethyl phosphorylcholine) generated by surface-initiated polymerization 
reactions.217, 234, 235  Furthermore, the fibrinogen adsorption levels for the microgel 
coating are also higher than fibrinogen adsorption values (< 10 ng/cm2) reported for glow 
discharge plasma-deposited tetraethylene glycol dimethyl ether densely cross-linked 
coatings (“tetraglyme”).146, 202  The differences in protein adsorption resistance among 
these coating technologies probably arise from differences in the architecture/structure of 
the PEG chains as the chain length and grafting density strongly influence “non-fouling” 
behavior.116, 217  An alternative explanation for the higher values of adsorbed fibrinogen 
to the microgel coatings is that there are spaces between microgel particles below the 
resolution of the AFM rendering that provide sites for protein adsorption.  This potential 
limitation could be addressed by using a different deposition technique or multi-layers of 
microgel particles.  Finally, it is important to note that additional experiments with more 
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complex protein solutions, such as plasma, are required to fully characterize the protein-
adsorption resistant properties of these coatings.   
Microgel-coated PET exhibited significant reductions in in vitro cell adhesion and 
spreading compared to untreated PET for both an established murine macrophage cell 
line and primary human monocytes/macrophages.  The reduced levels of cell adhesion 
and spreading on microgel-coated surfaces provide indirect evidence for the lack of 
adsorption of cell-adhesion promoting proteins.  We observed high levels of viability 
between surface conditions, so we do not attribute the differences in adherent cell 
numbers and spreading to differences in cell viability between the surfaces.  These cell 
adhesion results are consistent with previous reports of very low in vitro 
monocyte/macrophage adhesion to PEG-functionalized materials such as tetraglyme and 
PEG-star coatings.188, 220  In contrast, other studies showed high monocyte/macrophage 
adhesion to surfaces grafted with PEO polymers or PEG-containing interpenetrating 
networks;138, 149 however, in vitro macrophage fusion into foreign body giant cells was 
significantly decreased on these coatings.  The reason(s) for these discrepancies in 
monocyte/macrophage adhesion among PEG-based coatings remains poorly understood.  
These PEG-based coatings significantly reduce protein adsorption, albeit to different 
extents, and prevent adhesion of other cell types such as osteoblasts and endothelial cells.  
Possible explanations include (i) differences in adhesion receptor repertoire or numbers 
between primary monocytes/macrophages and other cell types and (ii) increased cell 
type-dependent degradation/modification of the underlying PEG coating. 
We evaluated acute inflammatory cellular responses to microgel coatings in a 
murine intraperitoneal implant model.  Microgel coatings significantly reduced the 
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number of adherent leukocytes compared to uncoated PET at 48 h of implantation.  
Similar differences were observed in a small number of samples implanted for 16 h.  
These reductions in in vivo leukocyte adhesion for the microgel coatings are in good 
agreement with our in vitro cell adhesion findings.  Furthermore, analysis of cytokine 
expression in adherent leukocytes demonstrated that microgel coatings reduced 
expression of the pro-inflammatory cytokines TNF-α, IL-1β, and MCP-1 compared to 
untreated microgel coatings following 48 h implantation.  This analysis is based on 
comparing equal numbers of cells; because microgel-coated implants contained 4.6-fold 
fewer cells than untreated PET implants, we expect that the total cytokine load will be 
significantly reduced for the microgel-coated implants.  Differences in cytokine 
expression were only detected for adherent cells and were not evident in cells isolated 
from lavage fluid, suggesting that adhesion to the implant was necessary for increased 
cytokine expression.  Taken together, these results indicate that microgel coatings reduce 
acute inflammatory cell adhesion and cytokine expression in vivo.  Finally, we note that 
the use of flow cytometry for analysis of cytokine expression provides a sensitive and 
powerful “per cell” assay that allows direct comparisons between cell populations, 
especially when compared to population-averaged assays such as ELISA.  However, the 
flow cytometry-based assay is limited to measuring intracellular, but not secreted, 
cytokines and provides relative (not absolute) measurements. 
The significant reductions in leukocyte adhesion and activation (cytokine 
expression) for microgel-coated PET contrast with reports for in vivo leukocyte adhesion 
to PEG/PEO-coated materials.188, 224, 236  For instance, Horbett and colleagues 
demonstrated high levels of leukocyte adhesion to tetraglyme coatings after 1-day 
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subcutaneous implantation,188 even though they reported reduced in vitro adhesion of 
monocytes/macrophages.139  These investigators attributed the increased levels of in vivo 
leukocyte adhesion to degradation of the tetraglyme coating and inadequate non-fouling 
behavior.  Interestingly, in vitro cell adhesion studies in the presence of whole blood or 
10% autologous plasma revealed increased levels of leukocyte adhesion and spreading, 
consistent with the in vivo observations.  The differences in adhesive activities between 
various media conditions (whole blood, 10% plasma, and 10% serum) suggest that 
differences in protein adsorption, possibly fibrinogen, account for the observed 
responses.  This possibility warrants further examination.  Nonetheless, it is evident from 
the preceding discussion that there is no simple correlation among protein adsorption, in 
vitro monocyte/macrophage adhesion, and in vivo leukocyte adhesion for PEG-based 
coatings.  
Several mechanisms could explain the ability of microgel coatings to significantly 
reduce in vivo leukocyte adhesion and cytokine expression, especially when considering 
that these coatings exhibited higher levels of protein adsorption compared to tetraglyme 
and other PEO-based films.  First, the higher levels of adsorbed proteins may be due to 
adsorption in spaces between microgel particles that are inaccessible to cells, resulting in 
dense conformal coatings with respect to the cells.  Alternatively, because our assembly 
process deposits a high volume polymer film (swollen microgel coatings are ~ 300 nm 
thick, tetraglyme coatings are 100 nm146) it is possible that the microgel coatings undergo 
slower overall degradation than other coatings.  Finally, an intriguing possibility is that 
the topography, in combination with the surface chemistry, of the microgel coating 
reduces leukocyte adhesion.  Siedlecki et al. recently demonstrated that sub-micron 
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surface features (pillars) reduce platelet adhesion and activation.237  Regardless of the 
underlying mechanism(s) responsible for the observed acute cellular responses, additional 
analyses with longer implantation times to examine chronic inflammatory responses and 
fibrous encapsulation are required to establish the potential of this microgel technology as 
a coating strategy for biomedical devices. 
 
CONCLUSION 
We present a coating strategy based on thin films of poly(N-isopropylacrylamide-
co-acrylic acid) hydrogel microparticles cross-linked with poly(ethylene glycol) 
diacrylate.  Simple spin coating and cross-linking of these particles to substrates 
generated conformal coatings that significantly reduced fibrinogen adsorption and in vitro 
adhesion and spreading of an established macrophage cell line and primary human 
monocytes.  More importantly, these coatings reduced leukocyte adhesion to polymer 
implants and attenuated the expression of pro-inflammatory cytokines in vivo.  These 
microgel coatings can be applied to biomedical implants as a protective coating to 
attenuate biofouling as well as leukocyte adhesion and activation in biomedical and 





CHRONIC INFLAMMATORY RESPONSES TO MICROGEL-





Although biomaterials and implantable devices are widely used to treat a variety 
of medical conditions, they elicit a host foreign body response (FBR) that often impairs 
wound healing and tissue remodeling.1  The severity and extent of the response to an 
implanted material directly affects the probability for its successful integration.  
Inflammatory responses significantly interfere with the biological performance of these 
devices, often resulting in failure that may require secondary surgeries and ultimately 
puts a patient’s health at risk.  Short-term or temporary implants, such as degradable 
scaffolds, may not cause extensive issues.  However, inflammatory events cause a range 
of adverse responses on long-term or permanent implants including thrombogenic 
responses on vascular grafts,2, 3 degradation and stress cracking of pacemaker leads,4, 5 
tissue fibrosis surrounding mammary prostheses,6 reactive gliosis around neural probes,9 
degradation in glucose biosensor function,10, and generation of wear debris around 
orthopedic joint prostheses.7, 8     
Chemicals released from cells and injured tissue continue to mediate the response 
proximal to the implant,39 and these persistent inflammatory stimuli lead to insufficient 
healing of tissue at the device interface.  Fibrous capsule formation around the implant 
and the presence of foreign body giant cells (FBGCs) at the tissue-material interface are 
the hallmarks of a chronic phase inflammatory response.  The αMβ2 integrin and 
macrophage mannose receptor (MMR) have been identified as critical components for 
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FBGC formation.84  Although the molecular mechanisms leading to macrophage fusion 
have not been fully elucidated, soluble molecules, signal transductors, and numerous 
receptors are likely involved.15  FBGCs have been implicated in biodegradation of 
polymeric implants through surface oxidation and enzymatic degradation.16, 17, 51  Multi-
nucleated giant cells have been observed in chronically inflamed tissues, yet the 
physiological significance and precise role of FBGCs at the tissue-material interface is 
poorly defined.  The cell-cell interactions of the FBR are quite complex, and the overall 
biological response to implanted materials is likely a composite of macrophages, 
fibroblasts, lymphocytes, and FBGCs.  Further elucidation of the molecular events 
governing inflammation will aid in the development of implantable materials with more 
appropriate host responses. 
Significant research efforts have focused on modifying material properties to 
generate implants that appropriately integrate with the host tissue while eliciting minimal 
undesirable effects.  A common approach to reduce inflammatory responses is the use of 
non-fouling (protein adsorption-resistant) thin-layer polymeric coatings, which have been 
developed in various forms including polymer brushes and thin or bulk hydrogels.  
Although many of these methods have been effective when tested in vitro, these coatings 
usually exhibit high levels of adherent leukocytes, persistent inflammation, and fibrous 
encapsulation of the implant.161, 170, 188  Long-term tissue fibrosis is particularly limiting 
for interactive implants such as biosensors, biomedical leads and electrodes, encapsulated 
cells, and drug delivery systems, because it impedes exchange of nutrients and cellular 
byproducts with the surrounding medium.10, 18-24  By controlling capsule thickness, 
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implant coatings may have the ability to maintain an open exchange of key biomolecules 
and extend the in vivo lifetime of these constructs.         
Previously, we engineered and characterized a hydrogel-based coating composed 
of pNIPAm-co-AA microgel particles cross-linked with PEG diacrylate tethered onto a 
poly(ethylene terephthalate) (PET) substrate.238  PET was chosen as the base material 
because this polymer is used in many biomedical devices, including sutures, vascular 
grafts, sewing cuffs for heart valves, and components for percutaneous access devices. 
PET elicits acute and chronic inflammatory responses characterized by leukocyte 
adhesion and fibrous encapsulation.65, 226  Our previous results showed that these 
microgel coatings reduced events associated with acute inflammation (i.e. protein 
adsorption and cell adhesion) and significantly reduced leukocyte recruitment and 
cytokine expression in vivo at early time points.238  In the present study, we evaluated 
chronic host responses to these microgel coatings.  We demonstrate that these conformal 
microgel coatings reduce fibrous capsule thickness and alter the cellular composition at 
the implant interface. 
 
 
MATERIALS AND METHODS 
Sample preparation 
Thin sheets of poly(ethylene terephthalate) (AIN Plastics/ThyssenKrupp 
Materials NA, Madison Heights, MI) were cut into disks (8 mm diameter) using a sterile 
biopsy punch (Miltex Inc., York, PA) and rinsed briefly in 70% ethanol to remove 
contaminants introduced during the manufacturing process.  Microgel particles were 
synthesized with 10 mol% acrylic acid as a co-monomer to incorporate functional groups 
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for future modification.  pNIPAm-co-AA microgel particles (100 mM total monomer 
concentration) were synthesized with 2 mol% PEG diacrylate (M.W. 575) by a free 
radical precipitation polymerization method and deposited on the surface of PET disks 
using a spin coating process as previously described.122  Unmodified PET disks were 
used as controls. 
Self-assembled monolayers (SAMs) of alkanethiols on gold were used as a 
reference material, since they have been extensively characterized as non-fouling 
substrates.30  Gold-coated substrates were prepared by sequential deposition of titanium 
(100 Å) and gold (200 Å) films via an electron beam evaporator (Thermionics 
Laboratories, Hayward, CA, 2 x 10-6 Torr, 1 Å/s) onto clean PET disks (8mm diameter).  
Self-assembled monolayers were prepared by immersing gold-coated slides in a 1.0 mM 
solution of tri(ethylene glycol)-terminated alkanethiols (HS-(CH2)11-(OCH2CH2)3-OH; 
EG3) in ethanol for 4 h.  Self-assembled monolayers were then rinsed in ethanol and 
deionized H2O.239 
After surface functionalization, all samples were rinsed in 70% ethanol on a 
rocker plate for 4 days, changing the solution daily to remove endotoxin contaminates, 
and were stored in 70% ethanol until use.  Samples contained 10-fold lower levels of 
endotoxin than the United States Food and Drug Administration’s recommended 0.5 
EU/mL,240 as determined by the LAL chromogenic assay (Cambrex, East Rutherford, 
NJ).  Prior to use, samples were rinsed three times in sterile phosphate buffered saline 





Samples (unmodified PET, microgel-coated PET, or EG3-coated PET; n = 8 
samples/group) were implanted subcutaneously following IACUC-approved procedures 
to evaluate the chronic phase foreign body response.  Male 5-6 wk old Wistar rats 
(Charles River Laboratories, Wilmington, MA) were anesthetized by isofluorane.  A 
single 1-cm incision was made on the dorsum proximal to the spine, and a subcutaneous 
pocket laterally spanning the dorsum was created.  Sterile samples (two per subject on 
either side of the spine) were implanted, and the incision was closed using sterile wound 
clips.  After four weeks, rats were sacrificed using a CO2 chamber and samples were 
explanted, rinsed in sterile PBS, and fixed in formalin.  Samples were carefully explanted 
with the surrounding tissue intact to avoid disrupting the cell-material interface.  Explants 
were bisected in order to avoid edge effects and standardize the sectioning location for 
analysis, and they were paraffin-embedded for histological processing.   
 
Histological staining of explants 
Histological sections (5 μm thick) were stained for various markers.  A Verhoeff-
van Gieson kit (Accustain® Elastic Stain kit from Sigma-Aldrich, St. Louis, MO) was 
used to stain collagen (pink), elastin fibers (black), and nuclei (dark blue).  Sixteen total 
fields per sample (eight fields on both the muscle and skin sides of the implant) were 
acquired using a high magnification 60X Plan Apo Nikon objective (1.40 NA).  
ImagePro software (Media Cybernetics, Silver Spring, MD) was used to quantify fibrous 
capsule thickness.  Results shown represent 4-7 animals per treatment group from a 
single implantation experiment. 
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Sections were also stained using immunohistochemical methods to determine the 
inflammatory cellular profile at the cell-material interface.  Following proteolytic antigen 
retrieval with pronase (1 mg/mL solution for 10 min), sections were incubated in a mouse 
monoclonal antibody against the CD68 antigen of macrophages (clone ED1, AbD 
Serotec, Raleigh, NC), a biotinylated secondary antibody, and an avidin-linked alkaline 
phosphatase-based developing reagent (Vectastain® ABC-AP Kit, Vector Labs, 
Burlingame, CA), and counterstained with hematoxylin.  Control sections (secondary 
antibody-only controls and tissue-specific controls) confirmed specificity of the primary 
antibody for this marker.  Sixteen total fields per sample (eight fields on both the muscle 
and skin sides of the implant) were acquired using a high magnification 60X Plan Apo 
Nikon objective (1.40 NA).  Images were blindly scored for total nuclei, CD68+ cells 




Data are presented as mean ± standard error.  Statistical analysis was performed 
by ANOVA using Systat 11.0 (Systat Software Inc., San Jose, CA).  Pair-wise 
comparisons were performed using Tukey post-hoc tests with a 95% confidence level 







Fibrous capsule formation surrounding implants 
Implanted materials were evaluated using an established subcutaneous rat model 
to determine the extent of chronic inflammation.1  Unmodified PET, EG3-terminated 
SAMs coated on PET, and microgel-coated PET disks were randomized and implanted 
for 4 wk.  Explants were processed histologically, and sections were analyzed for fibrous 
capsule development using a Verhoeff van Gieson kit to stain collagen and elastin fibers; 
all nuclei were counterstained for reference (Figure 6.1).  The capsule was defined as the 
dense tissue adjacent to the implant, and image analysis of high magnification images 
was used to measure capsule thickness as the perpendicular distance starting at the 
capsule-implant interface and moving outward.  Measurement of fibrous capsule 
thickness following subcutaneous implantation is a standard measure of chronic 
inflammation to synthetic materials.1 
Unmodified PET controls promoted formation of a thick and dense collagenous 
fibrous capsule (Figure 6.1a).  Importantly, microgel-coated samples (Figure 6.1c) 
significantly reduced fibrous capsule thickness by 22% compared to unmodified PET 
controls, as quantified in Figure 6.1d (p < 0.04).  No significant differences were 
detected between microgel-coated PET and EG3 SAM or PET and EG3 SAM (Figure 
6.1b).  The average capsule thickness was 112.3 ± 5.1, 98.7 ± 2.4, and 87.3 ± 2.9 μm for 
PET controls, EG3 SAMs, and microgel-coated samples, respectively.  In addition, the 
thinner fibrous capsules surrounding microgel samples also appear less compact and 
structurally ordered than PET controls, which tended to have highly organized collagen 
fibers deposited along the entire implant length. 
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The density of total cells present in the fibrous capsule was scored using 
counterstained nuclei, and sections were quantified in 100 μm increments along the 
implant interface (Figure 6.1e).  Both EG3 SAM- and microgel-coated samples contained 
significantly fewer (33% and 39%, respectively) capsule-associated cells than their 
unmodified PET control counterparts (p < 5.6x10-3 and 0.01, respectively).  The average 
cell density was 51.2 ± 2.2, 34.5 ± 1.0, and 31.1 ± 1.2 cells per 100 μm length of implant 
for PET controls, EG3 SAMs, and microgel-coated samples, respectively.  These results 
demonstrate that microgel coatings modulate both thickness and cell density of fibrous 
capsules surrounding implanted biomaterials.  Additionally, these coatings may alter 





Figure 6.1: Fibrous encapsulation of implanted biomaterials.  Biomaterials were 
implanted subcutaneously in the rat dorsum for 4 wk.  Explants were evaluated by 
staining collagen (pink), elastin (black), and nuclei (black).  Representative images taken 
with a 60X objective are presented for unmodified PET (a), EG3 SAMs coated on PET 
(b), and microgel-coated PET (c) disks, and the original implant location is designated. 
Black arrows indicate capsule measurements.  Microgel coatings effectively reduced 
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fibrous capsule thickness by 22% compared to unmodified PET controls as quantified in 
(d), * p < 0.04.  The density of capsule-associated cells was also significantly reduced in 
microgel-coated samples (* p < 5.6x10-3) and EG3 SAMs (§ p < 0.01) compared to 
unmodified PET controls as quantified in (e).  Data is represented as the average value ± 





Inflammatory cell profile at the implant interface 
Explant sections were processed to evaluate the composition of cells at the 
implant-tissue interface (Figure 6.2).  Immunohistochemistry was used stain for the 
CD68 antigen, a classical marker of monocytes and tissue macrophages, and all nuclei 
were counterstained for reference.  Images were scored for total CD68+ cells containing 
one nucleus (macrophages) and CD68+ cells fused to form multi-nucleated foreign body 
giant cells.   
High magnification images of unmodified PET controls (Figure 6.2a), EG3 SAM 
coatings (Figure 6.2b), and microgel-coated disks (Figure 6.2c) revealed that CD68 
staining was localized to the capsule, primarily along the capsule-implant interface.  All 
implanted samples, regardless of coating, contained similar levels of CD68+ cells as 
quantified in Figure 6.2d (no differences among treatment groups).  The average number 
was 19.5 ± 1.8, 14.9 ± 0.9, and 20.4 ± 1.1 CD68+ cells per 100 μm of implant length for 
PET controls, EG3 SAM, and microgel-coated samples, respectively.  CD68+ cell counts 
were then normalized to total cells in the fibrous capsule (as quantified in Figure 6.1e) to 
determine the relative numbers of macrophages in the capsule.  Microgel-coated samples 
contained significantly higher relative levels of macrophages than either unmodified PET 
controls or EG3 SAM (Figure 6.2e, p < 0.02 for both).  The average values were 37.8 ± 
10.4, 41.0 ± 6.5, and 68.1 ± 5.8 % CD68+ cells for PET controls, EG3 SAMs, and 
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microgel-coated samples, respectively.  It should be noted that this marker can potentially 
stain CD68 antigens in both adipose tissue241 and fibroblasts,242 the latter of which are 
also localized in the fibrous capsule and participate in collagen deposition.  Although 
F4/80 is the classical macrophage marker and may be the most specific to the 
macrophage lineage, antibodies were not available in the species-specific clone necessary 
for our experiments. 
Sections were also scored for multi-nucleated FBGC, designated by black arrows 
(Figure 6.2f).  Few samples contained extensive development of multi-nucleated FBGC.  
The average values were 4.1 ± 1.3, 1.4 ± 0.4, and 5.9 ± 0.8 FBGCs per mm of implant 
length for PET controls, EG3 SAM, and microgel-coated samples, respectively.  Numbers 
of FBGC per sample ranged from 1.4-11.1 and 3.0-11.8 cells/mm implant length for PET 
controls and microgel-coated disks, respectively.  However, no statistical differences 








Figure 6.2: Immunostaining of capsule-associated macrophages and foreign body 
giant cells.  Biomaterials were implanted subcutaneously in the rat dorsum for 4 wk.  
Explant sections were stained via immunohistochemical methods for macrophage marker 
CD68 (pink) and counter-stained with hematoxylin to label nuclei (blue).  Representative 
images taken with a 60X objective are presented for unmodified PET (a), EG3 SAMs 
coated on PET (b), and microgel-coated PET (c) disks, and the original implant location 
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is designated.   Total CD68+ cells were quantified in (d), but no statistical differences 
were found between treatment groups.  (e) When normalized to total capsule-associated 
cells (from Fig. 6.1e), unmodified PET and EG3 SAM controls both contained 
proportionately less CD68+ cells than microgel-coated PET (§  and * p < 0.02).  
Multinucleated CD68+ cells (FBGCs) at the cell-implant interface were also quantified 
(f), but no statistical differences were found between treatment groups.  FBGCs are 
designated by black arrows.  Data is represented as the average value ± standard error of 





We have engineered a hydrogel-based polymeric coating composed of PEG-
crosslinked pNIPAm-co-AA microparticles, which are applied to PET substrates using a 
spin coating method with high reproducibility to generate a conformal monolayer.122  
This coating strategy offers many advantages over traditional surface modification 
methods, including precise control over particle synthesis, the ability to generate complex 
architectures including “mosaic” coatings containing variations in particle composition or 
spatial arrangement, and deposition onto biomedically-relevant materials.  We have 
demonstrated these coatings reduce protein adsorption and leukocyte adhesion.89, 122  
Importantly, these microgel coatings have effectively reduced leukocyte adhesion and 
activation, as well as expression of pro-inflammatory cytokines, to biomedical polymer 
implants in vivo at acute time points.238  The results of the current study demonstrate that 
our microgel coatings also modulate chronic inflammatory events, including fibrous 
capsule thickness and cell density within the capsule. 
Research efforts have focused on modifying material properties using various 
anti-inflammatory surface coatings, including both passive and active strategies, to 
modulate biomaterial-mediated inflammation.151, 153, 161, 162, 177, 243  Since polyethylene 
glycol has proven to be the most protein-resistant functionality,114 passive PEG-based 
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coatings have been used extensively in the development of implantable materials.  In 
contrast to passive non-fouling surface treatments, coatings presenting or delivering anti-
inflammatory agents offer a more directed approach to modulate cell behavior.  However, 
these types of drug delivery systems are limited by the amount of therapeutic molecule 
incorporated and the drug half-life and activity.  Although these materials have reduced 
biofouling in vitro, many of these coating strategies still exhibit high levels of adherent 
leukocytes and continued inflammation in vivo with fibrous encapsulation of the 
implant.161, 170, 188, 244  Measurement of fibrous capsule thickness following subcutaneous 
implantation represents a standard measure of chronic inflammation to synthetic 
materials.1   
Compared to uncoated PET controls. microgel-coated samples were surrounded 
by thinner, loosely organized fibrous capsules.  Microgel coatings reduced capsule 
thickness to approximately 85 μm, a similar thickness to that of dihydroxypropyl 
methacrylate (DHPMA) hydrogels (~ 60 μm thick capsule).121  Moussy and colleagues 
developed these DHPMA hydrogels as coatings for glucose biosensors, and they 
demonstrated a functional increase in sensor responsivity compared to controls when 
tested in vitro.121  These authors attributed the enhanced in vivo sensor performance to a 
reduced capsule thickness and improved analyte transport.  Other types of non-fouling or 
non-inflammatory materials have achieved varied levels of in vivo success in modulating 
fibrous encapsulation of implants.  Polyethylene glycol-based copolymers effectively 
reduced tissue fibrosis surrounding implanted glucose sensors, although these materials 
were evaluated after only 3 d implantation.147  Phosphorylcholine (PC)-based materials 
contained fibrous capsules of relatively similar thickness to those surrounding our 
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microgel-coated samples after 4 wk implantation, but this capsule thickness was not 
significantly reduced compared to their controls.126  Fluorinated diamond-like carbon has 
recently gained considerable interest in biosensor and blood-contacting applications due 
to its favorable coagulation responses; however, it yields much thicker fibrous capsules 
(~ 300 μm after 28 d implantation) than our microgel-coated samples.245  In vitro protein 
adsorption was suppressed by photochemically immobilized polymer coatings on silicone 
rubber substrates and by polyethylene oxide-like tetraglyme coatings, yet neither 
treatment significantly reduced fibrous capsule thickness when implanted 
subcutaneously.187, 188  In addition to reducing capsule thickness, capsules surrounding 
microgel-coated samples were populated by significantly fewer cells (39% less) than PET 
controls.  After 4 wk implantation, PC-based coatings also reduced cellular density by 
39% (~ 160 cell/mm2 compared to control value of ~ 270 cells/mm2).126  Our results are 
also consistent with another report of an implanted polyethylene oxide-based material, in 
which increased PEO content in these triblock copolymers decreased the cellular density 
during implantation.224  Although microgel coatings significantly reduce tissue fibrosis, 
our current study is limited in that only one time point (4 wk) was examined for chronic 
responses.  It will be important to conduct more extensive studies in order to determine 
inflammatory responses at longer clinically-relevant implantation times. 
It is likely that the dynamics and extent of fibrous capsule formation are affected 
by the underlying material, as well as implantation site.  Recent work suggests that 
material surface properties may influence both acute and chronic inflammatory events.112, 
113, 246-248  Using microspheres presenting –OH and –COOH groups, Tang and colleagues 
demonstrated that surface functionality modulates fibrous capsule formation, 
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inflammatory cell recruitment, and cell infiltration into microspheres; they found that the 
–OH group prompted the strongest capsule formation.113  However, variations in surface 
density of those groups had only a minor effect on the extent of fibrotic tissue reactions; 
the authors suggest that further increases in the density may be relatively ineffective ones 
as a threshold density value has been reached on the surface.  In another study, SAMs 
presenting various functionalities revealed that CH3-terminated samples recruited higher 
levels of inflammatory cells and caused significantly thicker fibrous capsule formation 
than either OH- or COOH-terminated surfaces.248  By systematically adjusting the length 
of alkyl side chains on poly(alkyl methacylates), Andersson et al. showed that surface 
molecular mobility influences cell recruitment and cytokine activity, as well as the extent 
of fibrous encapsulation.112  Results also suggest that material surface properties are 
associated with angiogenesis during tissue repair.247  Moreover, using well-defined 
features, surface topography was also shown to mediate early cellular responses, such as 
adhesion and proliferation.237, 249, as well as angiogenesis during the FBR.250  In addition, 
the site of implantation significantly affects leukocyte recruitment and expression of 
matrix metalloproteinases in vivo,111 as well as biosensor function.251  Regardless of the 
mechanism of in vitro biofouling resistance, there appears to be no clear trend among 
surface treatments for their ability to modulate tissue fibrosis in vivo.  In addition to 
surface chemistry and topography, it is likely that implantation site and host species also 
play a role in fibrotic responses.  Other possible explanations for these differences 
include presentation (surface density and orientation) of the non-fouling component (e.g. 
PEG), kinetics and activity of incorporated drugs (for active coatings), and material 
stability. 
 91
In this study, microgel coatings reduced fibrous capsule thickness by 22% 
compared to unmodified control samples.  Such a reduction may translate into increased 
device longevity and support proper in vivo performance, which would directly benefit 
patients by requiring fewer follow-up surgeries and causing less pain throughout a 
patient’s lifetime.  Nevertheless, functional testing in specific applications (e.g., glucose 
sensors, pacing leads, neural electrodes) is required to evaluate the potential of these 
microgel coatings to ameliorate chronic inflammatory responses to implanted devices.  
Fibrous capsules on the order of 85 μm thick (as in our current study) may still pose a 
significant barrier to certain implanted devices or therapeutics by blocking the key 
exchange of nutrients or impeding signal transduction to an external medium.  For 
example, Moussy and colleagues recently demonstrated a correlation between increased 
collagen deposition surrounding implanted glucose sensors and decreased sensor 
sensitivity; natural angiogenesis failed to overcome the barrier to glucose diffusion 
caused by the associated fibrous capsule.252  Bioprotective membranes have demonstrated 
enhancements in glucose sensitivity following implantation, possibly by protecting the 
inner analyte sensing layers from inflammatory macrophage activity.110  In another study 
using poly(L-lactic acid) (PLLA) sensor coatings, Reichert and colleagues recently 
demonstrated that surface texturing through porosity increases vascularization and 
decreases collagen deposition around implants.251  Despite increased vessel density, 
sensors with porous coatings experienced an initial rapid signal reduction before 
stabilization.  Other studies have suggested the requirement for an initial “break in” 
period during fibrous capsule formation, after which glucose sensitivity increases.18, 109  
These porous PLLA coatings displayed less variability in signal transduction throughout 
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the implantation period, probably because of better integration with the surrounding 
tissue.251  Although our current results are promising, it will be important to functionally 
evaluate these microgel coatings in the context of such devices to determine their efficacy 
and to evaluate effects of the microgel coating itself (~ 300 nm thick in swollen state) on 
baseline device performance.    
Although there were no differences among groups when comparing total CD68+ 
cell numbers, the microgel-coated samples contained proportionately more macrophages 
than unmodified PET controls.  Additional studies are needed to determine the 
inflammatory phenotype of these CD68+ cells, because macrophages regulate both 
inflammatory and regenerative responses to biomaterial implants.  Emerging data 
suggests that macrophage phenotype is dictated by initial stimuli, causing them to 
become pro- or anti-inflammatory.81  T lymphocytes generate distinct immune responses 
based on the cytokine profile they secrete, where IFN-γ stimulates pro-inflammatory 
(Th1) responses and IL-4 and IL-10 (among others) stimulate anti-inflammatory (Th2) 
responses resulting in very different metabolic programs.81  Macrophages and 
lymphocytes likely act in concert during inflammatory or regenerative responses, and 
research indicates that distinct M1- or M2-subtypes of macrophages also exist.50, 88  
“Alternatively activated” cells, such as alveolar and placental macrophages, functionally 
down-regulate inflammation and immunity and secrete anti-inflammatory mediators such 
as IL-10 and PGE2 to suppress Th1 responses.79  Further studies are necessary to identify 
the macrophage phenotype and determine their overall involvement in fibroblast 
recruitment and collagen deposition around these microgel-coated implants.   
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In the current study, there were no significant differences among treatment groups 
in levels of FBGC at the implant interface.  Recent work suggests that polyethylene oxide 
polymers may alter the foreign body reaction by affecting the density of FBGC 
surrounding implanted hydrogels.221  Other types of polymeric coatings, such as 
phosphorylcholine, have also effectively reduced FBGC formation after 28 d 
implantation.177  FBGC have been observed in chronically inflamed tissues and have 
traditionally been associated with a pro-inflammatory phenotype because of their 
capacity to degrade implanted biomaterials.  However, the precise role of FBGCs at the 
tissue-material interface is poorly defined.  Emerging research suggests two distinct 
possibilities: (i) macrophage fusion into FBGCs could be a mechanism for promoting 
inflammatory cell survival by escaping apoptosis,86 or (ii) FBGCs could serve a more 
wound healing function by maintaining the inflammatory response at a local, less 
activated level.41  Longer-term implantations of our microgel-based coatings are needed 
to determine any negative effects of associated FBGC on the implant or surrounding 
tissue.  Possible explanations for why we observed no significant differences among 
treatment groups in FBGC numbers include (i) effects of soluble factors on tissue 
fibrosis, and (ii) influence of surface-bound receptors on activity of inflammatory cells.  
A number of soluble mediators including extracellular matrix proteins (such as 
osteopontin) and inflammatory cytokines been shown to play a role in macrophage fusion 
and formation of FBGC.15, 189  Anderson and colleagues have demonstrated a requirement 
for the β1 integrin in macrophage fusion.41  In addition, other receptors including 
dendritic cell-specific transmembrane protein (DC-STAMP), for which inflammatory 
MCP-1 may be a ligand, and the macrophage mannose receptor is necessary for cell 
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fusion.84, 253, 254  It is possible that activity levels of these integrins are similar on cells 
participating in the FBR, regardless of the differences between implant surfaces that 
affects acute responses. 
Previously, we demonstrated that microgel coatings significantly reduce protein 
adsorption, leukocyte adhesion, and activation at acute times in vivo.122  One possible 
explanation for these observations is that temperature-induced deswelling of pNIPAm at 
physiological temperatures results in phase segregation of non-fouling PEG “loops” and 
subsequent presentation on the surface.89, 231  While the structure and presentation of 
PEG, including chain length and grafting density, may strongly influence protein 
resistance,116, 217 additional parameters likely affect chronic responses to implanted 
materials.  For example, our microgel coatings are covalently cross-linked onto the 
substrate, which likely imparts bio-stability in vivo.  Tang and colleagues recently 
demonstrated a correlation between the rate of material degradation and the degree of 
resultant inflammatory responses; they suggest that degradation products are potent 
triggers of phagocyte activation, including superoxide production.255  Other groups have 
reported material degradation following implantation, possibly due to oxidative effects of 
chemicals released by phagocytes, for both tetraglyme coatings and polyethylene oxide 
copolymer hydrogels.188, 221  The method of cross-linking PEG has also been shown to 
affect in vivo efficacy.94  Moreover, our assembly process deposits a high volume 
polymer film (swollen microgel coatings are ~ 300 nm thick), which may result in slower 
overall degradation than thinner coatings such as tetraglyme (100 nm thick).146  
Therefore, surface degradation may result in loss of non-fouling PEG activity and likely 
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plays a role in extensive capsule development.  Studies examining the degradation and 
stability of these coatings are still needed. 
In addition to influencing protein adsorption and cell adhesion, surface chemistry 
may also influence complement activation,56, 256, 257 providing an alternative route to 
chronic events.  In particular, surface hydroxyl (-OH) groups have been linked to 
leukocyte adhesion and contact activation of the complement system, possibly involving 
a direct covalent thioester linkage of complement fragment C3.257  Moreover, there is a 
proposed role for the C1q receptor (CD93) on monocytes/macrophages in activation and 
enhanced phagocytic capacity of targets opsonized with complement.258  It is evident that 
there is no simple correlation among protein adsorption, in vitro monocyte/macrophage 
adhesion, and in vivo leukocyte activities for PEG-based coatings.  Extensive research 
efforts should be focused on elucidating the molecular mechanisms governing material 
biocompatibility during the transition from acute to chronic events, including the 
dynamics of fibrous capsule development. 
This work provides the foundation for developing a microgel-based coating 
system incorporating various signaling agents and bioactive therapeutics within a low-
fouling background.  These “smart” delivery systems offer several advantages over 
passive methods, including highly controlled presentation of immunomodulatory agents, 
control over reaction kinetics, and versatility through hybrid designs.  Fibrous capsule 
thickness could potentially be reduced further using such complex coatings with tunable 
active release mechanisms to deliver anti-inflammatory agents, such as IL-1Ra, 
angiostatin, or dexamethasone, which have improved biological responses to implanted 
materials.161, 162, 176, 185, 259   
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CONCLUSION 
Using a model of chronic biomaterial-mediated inflammation, we demonstrate 
that surface coatings comprised of pNIPAm-co-PEG hydrogel microparticles reduce 
long-term fibrous encapsulation and alter the cellular composition at the implant 
interface.  Microgel coatings effectively reduced collagen capsule thickness by 22%, and 
those capsules appeared less compact and structurally ordered than PET controls.   These 
coatings also contained significantly fewer total cells within the capsule.  Our current 
results demonstrate that microgel particles can be applied as implant coatings to modulate 
inflammation and achieve more desirable chronic host responses in vivo, with the 








BASE MICROGEL COATINGS 
Biomaterial-mediated inflammation poses a complex problem, limiting the 
function of implanted devices.  Over the last few decades significant progress has been 
made toward the development of material surface treatments and coating strategies to 
prevent non-specific protein adsorption and leukocyte adhesion, the critical events of 
acute inflammation; it is generally believed that reducing such biofouling can ameliorate 
subsequent adverse responses.  However, many technologies that have modulated early 
events to some degree of success are still plagued by chronic phase host responses such 
as fibrous capsule formation.  By contrast, we have demonstrated that our novel 
pNIPAm-co-PEG microgel coatings significantly reduce adhesion and inflammatory 
activity at early time points of implantation.  More importantly, we have shown that these 
coatings also modulate chronic inflammatory events by reducing development and 
organization of the fibrous capsule and maintaining cell density at low levels around the 
implant interface.   
Further evaluation of these coatings is critical in order to determine the extent of 
vascularization within the capsules, as this could indicate the propensity for wound 
healing and regeneration of the surrounding tissue.  Additionally, it would be interesting 
to determine the contributions of other proteins to capsule development.  For example, 
fibronectin is required for collagen assembly,203, 204 and it also modulates chronic 
inflammatory responses.212  Recent evidence has also revealed important roles for 
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osteopontin expressed by inflammatory cells, including macrophage recruitment and 
contribution to wound fibrosis,189 and other findings suggest it inhibits FBGC 
formation.260  The precise role of FBGCs at the tissue-material interface is poorly 
understood; therefore, further investigation is critical in understanding the role of these 
proteins and the inflammatory nature of multinucleated FBGC. 
 
 
BIOACTIVE MICROGEL COATINGS 
Future coating designs will probably need to be material and application-specific 
in order to achieve the desired in vivo response.  Biologically interactive implants are 
gaining considerable interest.  Tunable, stimuli-responsive materials and biomimetic 
molecules may be able to actively direct cell behavior and activity surrounding the 
implant, encouraging more desirable interactions.33, 34  These delivery systems offer 
several advantages over passive methods, including highly controlled presentation of 
immunomodulatory agents, control over reaction kinetics, and versatile designs.   
Although significant progress has been made in understanding the mechanisms of 
initial protein adsorption onto surfaces, the molecular events driving macrophage and 
FBGC phenotype and activities at the implant interface are poorly understood.  
Monocytes and macrophages express the leukocyte-specific αMβ2 integrin, which is 
capable of interacting with a variety of ligands and mediating cell-cell and cell-substrate 
interactions.41, 71-73  Importantly, integrins are key mediators of signal transduction 
between the extracellular and intracellular environments, and they also play a role in 
focal adhesions and cellular migration.40, 70  Studying the interactions of protein and 
surface chemistry effects has been difficult due to the complexity of macrophage receptor 
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expression, protein adsorption and conformation on the biomaterial surface, and 
maturation and fusion into FBGCs.  Moreover, little is known about integrin-dependent 
behavior in macrophages.  Macrophage adhesion to two particular motifs, P2 (from 
fibrinogen) and RGD (from fibronectin), via the leukocyte-specific αMβ2 integrin has 
been implicated in inflammation.41, 71-73  However, we do not known how integrin 
binding numbers and specificity regulate macrophage function.  It is possible that 
different densities or combinations of ligands differentially regulate macrophage 
activities.   
This thesis work provides the foundation for developing a hydrogel-based coating 
system incorporating various signaling agents and bioactive therapeutics within a low-
fouling background.  By creating a tunable system to interact with macrophages, the key 
mediators of inflammation, our long-term goal is to systematically control macrophage 
adhesion and subsequent activities.  We will take advantage of our ability to engineer 
well-defined interfaces to direct integrin binding and evaluate macrophage responses to 
these interfaces.  Therefore, bioadhesive ligand motifs P2 and RGD have been selected 
for tethering to microgel particles to address the above issues.  Using these coatings with 
embedded signals to control integrin binding, we will address the current knowledge gap 
by providing vital information about various integrin-dependent macrophage behaviors.  
We will determine the effects of ligand density and presentation on macrophage adhesion 
to biomaterial surfaces, subsequent activation, signaling, cytokine release, and their 
fusion into FBGCs.  Using blocking antibodies, we will also determine the contributions 
of β1 and β2 integrins to these activities.  These proposed studies represent a systematic 
evaluation of macrophage functions to well-defined biomaterial interfaces.   
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Microgel coatings separately presenting tethered (static) bioadhesive motifs of P2 
or RGD have been developed (Figure 7.1).  Using standard peptide chemistry, these 
biomolecules have been conjugated to microgel particles using 2% of the available 
acrylic acid co-monomer groups.  Early results were promising and indicated the system 
was successful; however, the project has encountered numerous problems with 
reproducibility using the current methods.  Although it is currently unclear, possible 
explanations for these problems include reduced bioactivity after tethering or improper 
peptide exposure.  To determine appropriate bioactivity of these ligands, we conducted 
cell adhesion studies at early time points (48 h).  We created model mixed SAM surfaces 
(EG3/EG6-COOH alkanethiols) on gold substrates using previously characterized 
techniques,239 and standard peptide chemistry was used to conjugate peptides to 2% of 
the SAMs.261  Murine macrophages and NIH 3T3 fibroblasts (for their known adhesive 
behavior on RGD-tethered surfaces) were then cultured on samples, and results from 
multiple experiments indicated that both RGD and P2 retained their bioactivity on model 





Figure 7.1: Bioactive microgel coating presenting tethered 
bioadhesive motifs of P2 or RGD to elucidate integrin-




To determine whether cells have proper access to these peptides, additional 
studies may be necessary to alter the microgel dimensions and determine an optimal 
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tethering distance.  For example, short PEG spacer arms could be incorporated into the 
microgel particles to extend the tethered ligands further from the non-fouling 
background, providing cells more access to elicit binding and signaling events.262, 263  
Receptor binding is highly dependent on the structural context of the ligand, and 
appropriate spacing at the nano level is even critical to retain biological activity.264-266  
Therefore, it is possible that these ligands are oriented improperly and cannot facilitate 
interactions with cells.  While unlikely, it is also possible that higher concentrations of 
ligand are required to elicit cellular responses; however, such concentrations are limited 
by material cost and are thus experimentally impractical to pursue. 
Additional formulations of microgel particles could be devised using alternative 
synthesis techniques to create particles of much smaller size, relative to the ligands.130  
Moreover, alternative structures, such as the core-shell microgel system, could be used to 
incorporate amine groups into the shell for more effective bioconjugation.  Instead of 
tethering ligands, which possibly reduces its bioactivity, such a core-shell system could 
be employed to incorporate biomolecules within the core structure for controlled release 
by degradative mechanisms or endogenous stimuli.  In this way, the microgel system 
could be used to deliver anti-inflammatory agents, such as IL-1Ra or angiostatin, to 
abrogate inflammatory events rather than control cell binding.185, 259 
The long-term goal of this work is to engineer microgel coatings that dynamically 
present bioactive ligands in a non-fouling background, creating surfaces that interact with 
macrophages in order to elicit specific host responses and direct the events of 
inflammation.  Multilayered coatings constructed of an inner microgel core surrounded 
by an outer microgel shell will support temporally controlled cell adhesion to our 
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surfaces.  Using dynamic and stimuli-responsive interfaces, the presentation of surface-
bound moieties can be coordinated with specific stages of inflammation, as directed by 




Figure 7.2: Stimuli-responsive microgel coatings to 





These bioactive approaches may create less inflammatory macrophages and 
attract wound healing cells.  Using this versatile microgel system, we intend to provide 
insight into the complex interactions of macrophages with biomaterials that may enable 
more well-designed implants or devices and extend their in vivo lifetime.  If successful, 
this microgel technology has the potential to significantly improve device performance 
by limiting deleterious cellular effects and fibrous encapsulation at the biomaterial-tissue 
interface.  Microgel coatings could then be developed for a wide variety of biomaterials 





COVALENT TETHERING OF FUNCTIONAL MICROGEL FILMS 




* Modified from N Singh, AW Bridges, AJ García, and LA Lyon.  Covalent tethering of functional 
microgel films onto poly(ethylene terephthalate) surfaces.  Biomacromolecules 8 (2007): 3271-3275. 
 
AW Bridges contributed scientifically to this work, including in vitro cell culture and adhesion studies, and 





Recently there has been an increasing interest in developing biotolerant polymeric 
surfaces that have the ability to support or immobilize biological functionalities tailored 
for specific biotechnological and medical applications.267-270  As an important example, it 
is common to immobilize extracellular-matrix proteins (e.g., collagen, fibronectin) or cell 
signaling molecules on polymeric surfaces to yield functional biomaterials that have the 
ability to modulate cell adhesion, proliferation, and differentiation, thus mimicking a 
natural cellular environment.269, 271-274  
Another interesting class of polymeric materials with desirable properties for 
biotechnology is the hydrogel microparticle or microgel.  The synthesis, characterization 
and applications of stimuli-responsive microgels have been extensively studied over the 
past few years.38, 225, 231, 275, 276  Recently, Nolan et al. investigated the performance of 
poly(N-isopropylacrylamide) (pNIPAm) microgels cross-linked with short poly(ethylene 
glycol) (PEG) chains, as protein adsorption-resistant films.89  The PEG cross-linked 
pNIPAm microgels having poly(acrylic acid) as co-monomer, were assembled 
electrostatically by spin-coating onto a cationic glass substrate.  The results indicated that 
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glass surfaces coated with microgels showed reduced protein adsorption and cell 
adhesion in vitro, i.e. non-fouling behavior.  However, the potential of these microgel 
films as non-fouling base coatings for future biomedical implants cannot be probed and 
realized until they are assembled on a more flexible and biocompatible substrate than 
glass.  This motivated our current goal to design a flexible substrate-based microgel film 
with potential non-fouling and anti-inflammatory behavior for in vivo studies.  Equally 
important, we also aim to enhance the stability of the adherent microgel films in 
comparison with the Coulombically assembled film in biological environments by 
improvements in the surface chemistry.  
For in vivo studies of biomaterials, common desirable attributes for a model 
biomaterial (in this case, a polymer) include good mechanical strength, flexibility, 
chemical and physical stability in the biological environment, and a surface 
chemistry/composition that allows for facile biofunctionalization.  In view of these 
properties, poly(ethylene terephthalate) (PET) was chosen as a model biomaterial onto 
which we could deposit non-fouling microgel coatings in order to enhance its properties.  
PET has been extensively studied in biomaterial applications such as for sutures, vascular 
grafts, sewing cuffs for heart valves, and components for percutaneous access devices.277-
280  However, the PET surface is inert and hence not suitable for direct 
biofunctionalization.  Major efforts have therefore been undertaken to introduce various 
functionalities onto the PET surface, such as amine, carboxyl, and hydroxyl moieties, 
which can be further employed for the covalent immobilization of biomacromolecules.271, 
281, 282  It is especially desirable that the methods used for the chemical modification are 
confined to the polymer surface, without affecting the bulk/mechanical properties of the 
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substrate.  A suitable technique in this regard has been the chemical activation of the inert 
polymer surface by plasma treatment, which has already been employed to render PET 
surfaces hydrophilic and hence more biocompatible.283  It is also well known that the 
exposure of polymeric surfaces to a plasma along with oxygen treatment generates 
surface-active hydroperoxide species that can be used for the chemical grafting of desired 
chemical and biological functional groups.271, 281, 284-288  
Our method of functionalizing the PET with polymeric microgel films (Figure 
A.1) is derived from previous methods based on plasma-induced graft polymerization of 
poly-acrylic acid (pAAc).  Plasma- and ozone-induced graft polymerizations of various 
monomers on PET films, fibers, and fabrics have been demonstrated.271 287, 288  However, 
in order to make the method more general, and to give the adherent microgel film more 
stability in biological environments, we introduced onto the PET surface a photo-affinity 
label, viz., aminobenzophenone.  Upon excitation with UV irradiation, molecules of the 
benzophenone family have the ability to abstract an aliphatic hydrogen atom from any 
nearby polymer chain forming a covalent carbon-carbon bond.270, 289, 290  Due to the 
presence of a microgel in the close vicinity of the benzophenone, it can abstract hydrogen 
atom from the microgel and hence covalently attach the particles to the PET surface.  
Essentially, the benzophenone here serves as a glue between the base PET substrate and 






Figure A.1: Strategy for covalent tethering of microgels onto a poly(ethylene 





All materials were obtained from Sigma Aldrich unless otherwise specified.  The 
monomer NIPAm was recrystallized from hexane obtained from J.T. Baker before use.  
Poly(ethylene terephthalate) (PET) sheets were obtained from AIN Plastics; Marietta, 
GA.  All other chemicals were used as received. Formate buffer solution (pH 3.47, 10 
mM) was prepared from formic acid and NaCl obtained from Fisher Scientific.  
Poly(ethylene glycol) diacrylate (PEG) (PEG MW 575, Polysciences, Inc.) was used as 
received.  1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was purchased from 
Pierce.  Dimethyl sulfoxide (DMSO) was obtained from J.T. Baker.  Phosphate buffered 
saline (PBS) solution (pH 7.4, 10 mM) was prepared from NaCl (Fisher), Na2HPO4 (EM 
Science) and KH2PO4.  Water was distilled and then purified using a Barnstead E-Pure 
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system to a resistance of 18 MΩ and finally filtered through 0.2 μm membrane filter (Pall 




Poly(N-isopropylacrylamide) (pNIPAm) microgel particles (100 mM total 
monomer concentration) were synthesized with 2 mol % poly (ethylene glycol) (PEG) 
diacrylate (MW 575) by a free radical precipitation polymerization method.  For 
incorporating functional groups that can be later modified, the microgel particles were 
synthesized with 10 mol % acrylic acid as a co-monomer.  Briefly, 0.4979 g of NIPAm 
monomer, 0.7011 g of cross-linker PEG-diacrylate, and 0.0025 g of surfactant sodium 
dodecyl sulfate (SDS) were dissolved in 49 mL distilled, deionized (DI) water, and 
filtered through a 0.2 μm filter.  The solution was transferred to and stirred in a three-
neck, round-bottom flask, and heated to 70 °C while purging with N2 gas.  After reaching 
70 °C and purging for 1 h, 34.3 μL of acrylic acid was added, followed by the addition of 
0.0114 g (dissolved in 1 mL DI water) of ammonium persulfate (APS) to initiate the 
reaction.  The reaction was kept at 70 °C for 4 h.  The synthesized microgels were then 
filtered and cleaned by five cycles of centrifugation at 15,422 g for 45 min.  The 
supernatant was removed, and the particles were redispersed in DI water.  The particles 





PET Film Functionalization 
PET sheets were cut into 8 mm diameter disks using biopsy punches and briefly 
rinsed in 70% ethanol to remove contaminants introduced during the manufacturing 
process.  Graft polymerization of acrylic acid (AAc) on 8 mm PET films was done in two 
steps.  PET films were first placed in an 18 W RF Ar plasma (Harrick Scientific) 
connected to a vacuum pump (5 × 10-4 mbar) for 2 min.  Immediately after the Ar 
treatment, air was introduced into the plasma chamber and maintained at atmospheric 
pressure for 1 h to generate peroxide and other oxygen-containing functional groups on 
the PET surface.  The films were immediately transferred to a round bottom flask 
containing an N2 purged 25% (v/v) aqueous solution of acrylic acid.  The grafting 
reaction was carried out for 6 h at 50 0C, after which the films were washed in water 
overnight.  The degree of polymer grafting and hence the density of carboxyl groups on 
the PET surface can be controlled by varying the AAc concentration and reaction time.286  
The pAAc modified PET was further modified with 4-aminobenzophenone (ABP) using 
carbodiimide coupling.291  The coupling of 4-aminobenzophenone is done traditionally as 
a one-step reaction using N,N׳-dicyclohexylcarbodiimide (DCC) in organic media 
(DMSO).  However, we used an aqueous carbodiimide coupling strategy based on 
activation of carboxyl groups with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and further reaction with the ABP.  This is to 
avoid the formation of urea precipitate (the by-product in the DCC reaction), which is 
difficult to remove completely from the surface being modified.  The pAAc modified 
PET films were first activated by incubation in 2 mM EDC and 5 mM NHS in 10 mM 2-
(N-morpholino)ethanesulfonic acid (MES) buffer solution (pH 6.0) for 30 min at room 
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temperature.  The films were then and placed in 20 mM 2-mercaptoethanol solution in DI 
water to quench the EDC.  The activated films were then reacted with ABP in DMSO for 
2 h at room temperature.  The ABP modified films were washed in DMSO and immersed 
in 10 mM hydroxylamine solution to quench the reaction.  Finally, the films were washed 
in DI water.  
 
Carboxyl Group Determination 
The amount of pAAc grafting on the PET film surface was characterized by a 
colorimetric method based on Toluidine Blue O staining.281  Briefly, the grafted film was 
placed for 6 h at 30 °C in a 0.5 mM Toluidine Blue O solution prepared at pH 10.  The 
film was then removed and thoroughly washed with NaOH (pH 10) to remove any dye 
nonspecifically adhered to the surface.  The bound dye molecules were then desorbed 
from the film in a 50% acetic acid solution.  The final dye content was determined from 




A spin-coating process was used to deposit a layer of microgel particles onto the 
functionalized PET films.  The PET film was placed onto a glass slide, and the slide was 
placed onto the spin coater (Specialty Coating Systems) chuck and held in place by 
vacuum.  The rotor speed was maintained at 500 rpm.  Dried microgels were dispersed in 
a 10 mM formate buffer (pH 3.47) solution and one drop of the microgel solution was 
deposited onto the PET film while spinning.  After keeping the film on the spin coater for 
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100 s, a second drop of the microgel solution was deposited.  The PET film was left on 
the spin coater for additional 100 s and the film was allowed to dry.  Finally, another drop 
of microgel solution was deposited on the PET by the same process and the film was 
dried after 100 s of spinning.  This process was done on both sides of the PET films 
under dark conditions.  Each side of the PET, with the dried microgel film, was irradiated 
by a 100 W longwave UV lamp (Blak-Ray) for 30 min to covalently attach the microgels 
onto the PET surface.  The microgel-modified PET film was soaked in 10 mM phosphate 
buffer solution (pH 7.5) for 6 h and then washed with DI water. 
 
Atomic Force Microscopy  
All images were obtained in AC mode on an Asylum Research MFP-3D atomic 
force microscope (AFM).  Spring constants were calculated using the thermal method. 
Imaging and analysis was performed using the Asylum Research MFP-3D software 
(written in the IgorPro environment, WaveMetrics, Inc., Lake Oswego, OR).  An 
Olympus AC160 cantilever with k = 42 N/m, f0 = 300 kHz was used for imaging. 
 
In vitro cell adhesion  
The IC-21 murine macrophage cell line (ATCC; Manassas, VA) was used to 
determine the bioresistant properties of the microgel coated PET in vitro.  Cells were 
seeded at a density of 67,000 cells/cm2 on unmodified PET and microgel-coated PET 
disks in 24-well tissue culture-treated polystyrene plates in culture media containing 10% 
fetal bovine serum.  After 48 h, adherent cells were fluorescently stained with calcein-
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AM (Molecular Probes, Eugene, OR) and imaged using a Nikon TE-300 microscope to 
determine relative cell numbers and cell spreading on each surface. 
 
RESULTS AND DISCUSSION 
In order to deposit uniform films of microgels, the PET films had to be rendered 
amenable to robust particle attachment.  The approach described above (Figure A.1) 
involves surface activation in an Ar plasma followed by the introduction of air to 
introduce thermally-labile groups.  These thermally-labile groups thermally decompose to 
form radicals, thus initiating the polymerization of AAc to form pAAc-grafts on the PET 
surface.284-286  The carboxyl groups of the pAAc on the PET surface are subsequently 
used in the functionalization of the surface with photo-affinity label (ABP) using 
carbodiimide coupling chemistry.  We characterized the surface grafting density of pAAc 
by the Toluidine blue O dye binding assay. Figure A.2 shows UV-visible absorbance 
spectra of Toluidine blue O dye arising from various surface treatments.  Based on 
previous methods, by assuming a 1:1 ratio between the dye and the carboxylic acid 
groups, the OD at 633 nm gives a measure of the degree of grafting.281, 284  Thus, 
successful pAAc grafting of the PET surface is evidenced by an increase in the OD from 
~0.01 for the bare PET substrate to about 2.02 for the modified surface.  The color 
staining of the dyed films was very uniform across the samples, suggesting relatively 
uniform coating of the PET (data not shown).  For the pAAc grafted PET, we estimate 
about 1.4 ×10-7 moles of carboxyl groups and following the reaction with ABP, only 
about 1.1×10-8 moles of carboxyl groups are left on the surface.  Hence, this suggests that 
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the benzophenone modification of the PET results in a loss of ~92% of the carboxyl 





Figure A.2: Absorption spectra for desorbed Toluidine 
Blue O dye.  Spectra are shown for bare PET (black), 
poly(acrylic acid) grafted PET before (red) and after (blue) 





Our method of surface functionalization of the PET with photo-affinity labels 
results in a very efficient surface modification with the microgels.  Figure A.3 shows 3D 
renderings of AFM images obtained from a representative film.  It can be seen from the 
50 x 50 μm scan (Figure A.3b) that there are no uncoated areas in the interrogated 
region.  The microgels also form a dense conformal monolayer as indicated by the 10×10 
μm scan (Figure A.3c).  The unevenness in the microgel-coated PET is due to the uneven 












Figure A.3: 3D rendering of AFM images.  Representative images are shown for (a) 
bare PET, (b, c) and microgel-modified PET. 
 
 114
The benzophenone modification and photo-crosslinking are critically important 
steps for obtaining a stable monolayer, as suggested by Figure A.4.  Figure A.4a shows 
an AFM image of a microgel film that was spin-coated onto pAAc-grafted PET without 
benzophenone modification, followed by extensive washing.  It is clear that the coverage 
is sparse with only a few microgel particles retained on the surface.  Since covalent 
linkages are not possible in the absence of the photo-affinity group, the particles cannot 
remain adhered to the film during the washing step.  This poor coverage is probably also 
due, in part, to the anionic charge on both the microgels (due to the AAc co-monomers) 
and the film (due to the pAAc grafts).  In the case of benzophenone-modified surface 
(Figure A.4b) slightly more microgels are retained on the PET surface, presumably due 
to less Coulombic repulsion between the microgels and the modified PET.  In this case, 
the photo-irradiation step is omitted and again, no covalent attachment is possible.  
However, the best results are found for the pAAc-grafted PET surfaces modified by 
benzophenone and further photo-irradiated (Figure A.3b).  The photo-cross-linking is 
thus shown to provide a microgel film with excellent adhesion to the substrate and hence 






















Figure A.4: Effects of benzophenone modification and 
photo-crosslinking on microgel functionalization 
process.  3D rendering of AFM image of microgels spin 
coated onto pAAc-grafted PET (a) without benzophenone 
modification and (b) with benzophenone modification but 
without UV irradiation. 
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It is known that one of the key steps in the inflammatory host response to 
biomaterials is non-specific protein adsorption, which then mediates cell adhesion and 
spreading.1  Recent efforts in the field of biomaterials and medical implants have focused 
on developing non-fouling surface treatments to prevent this non-specific protein 
adsorption and cell adhesion.270, 292-294  Our group has previously shown the efficacy of 
PEG-containing pNIPAm microgels as protein and cell adhesion-resistant materials.89, 231  
In addition to their non-fouling behavior, the facile and well-controlled synthesis of 
highly monodispersed microgels in a range of sizes, ease of their biofunctionalization 
using various orthogonal chemical functionalities, and possibility of co-assembling varied 
microgels onto a single substrate to generate complex bio-interfaces makes them 
interesting candidates for biomedical implant coatings for modulation of inflammatory 
response.  We take advantage of these attributes to study and produce model biomaterials 
incorporating microgels that can be tested for their functionality.      
   Based on the AFM confirmation of a stable uniform monolayer of microgels on 
the PET surface, we tested the cell adhesion resistance of these surfaces in vitro.  IC-21 
macrophages were plated on substrates in culture media containing 10% serum.  This 
provides a rigorous test for bioresistance as cell adhesive proteins present in serum 
rapidly adsorb onto synthetic surfaces and mediate cell adhesion and spreading.  In 
contrast to bare PET films, which supported high levels of cell adhesion and spreading, 
microgel-functionalized PET films exhibited no macrophage adhesion over the 48 h test 
period (Figure A.5), indicating a stable cell adhesion-resistant coating.  We attribute the 
lack of cell adhesion to microgel-functionalized surface to the protein-resistant nature of 
the PEG cross-linked microgels.  The ability of microgel-coated surfaces to resist cell 
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adhesion and spreading was distributed throughout the entire sample, indicating uniform 
distribution of bioresistance.  The success of this surface functionalization strategy thus 
allows the study of the non-fouling behavior of the PEG cross-linked pNIPAm microgels 
in vivo and also gives us opportunities to develop more complex biomaterials 





Figure A.5: Macrophage adhesion to biomaterial surfaces.  
Representative images detail macrophage adhesion on samples of (a) 
bare PET and (b) PET covalently functionalized by microgels.  






In conclusion, we report a simple, scalable, and reproducible method of 
functionalizing PET with a conformal, dense film of hydrogel microparticles. The 
microgel layer is stable due to the covalent attachment of the microgels to the PET 
surface via a photo-affinity technique. This method can be easily extended for modifying 
the inert PET surface with any organic species, providing bioactive surfaces possessing 
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excellent stability. Note that the spin coating deposition method is used here mainly for 
speed, convenience, and potential scalability. However, it cannot be used to coat 
substrates with complex geometries and in such cases other deposition techniques must 
be employed. We are currently evaluating methods for dip-coating of microgels onto 
complex substrates. Future studies are also geared towards studying the stability and 
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